Antibodies having improved affinity
Patent Information
- Application Number
- EP2023737519
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-01-04
- Filing Date
- 2023-01-03
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for cancer, particularly those related to SHP2 and siglec expression abnormalities, lack effective compounds and methods to target and inhibit siglec proteins like siglecl2, which are associated with various cancers, including leukemia.
Development of antibodies that specifically bind to siglecl2, including variants with specific CDR sequences, to induce cell death, inhibit tumor immunosuppression, and facilitate antibody-dependent cellular cytotoxicity, which can be administered to treat cancer cells expressing siglecl2.
The antibodies effectively target and kill cancer cells expressing siglecl2, offering a potential therapeutic approach for treating cancers like acute myeloid leukemia and chronic myeloid leukemia by inducing cell death and inhibiting immunosuppressive mechanisms.
Smart Images

Figure IMGF000043_0001 
Figure IMGF000046_0001 
Figure IMGF000046_0002
Description
[0001] ANTIBODIES HAVING IMPROVED AFFINITY
[0002] RELATED APPLICATION
[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 296,174, filed on January 4, 2022. The entire teachings of the above application are incorporated herein by reference.
[0004] SEQUENCE LISTING
[0005] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing file, entitled 2197_1001USPRO_SL.txt, was created on January 3, 2022 and is 129,830 bytes in size. The information in electronic format of the Sequence Listing is incorporated herein by reference in its entirety.
[0006] BACKGROUND
[0007] The sialic acid binding-immunoglobulin type lectins (siglecs) are a large family of proteins consisting of fifteen members. They bind sialic acid glycans found on N-linked glycans and glycolipids (Duan and Paulson., 2020, Ann Rev Immunology 14, 365-395). Sialic acids are nine carbon anionic sugars with a Cl carboxyl group, a C5 N-acetyl group, and a glycerol side chain from C7-C9. Siglec extracellular domains include immunoglobulin (Ig) domains that are structurally similar to variable and constant regions of an antibody. CD33-related siglecs are family members thought to be derived from CD33 duplication of the CD33 gene. Sialic acid binding sites are present in the extracellular domains with a majority of siglecs having immunoreceptor tyrosine inhibitor motifs (ITIMs) within their intracellular domains. ITIMs are phosphorylated by src kinases and recruit src-homology 2 domain (SH2) containing phosphatases SHP-1 and SHP-2. SHP-1 and SHP-2 dephosphorylate signaling molecules in a variety of cellular activation signaling pathways.
[0008] Cancer is a leading cause of death worldwide. It is characterized by unchecked cell growth and proliferation. SHP2 is a known proto-oncogene shown to promote cell invasion, proliferation, and survival associated with various cancers. There remains a need in the field for compounds and methods to treat cancer, including SHP2-related cancers linked to abnormal siglec expression and / or function. The present disclosure addresses this need with related compounds and methods described herein. SUMMARY
[0009] In some embodiments, the present disclosure provides an antibody, wherein the antibody binds a sialic acid binding-immunoglobulin type lectin (siglec) and wherein the antibody includes at least one human antibody variable domain. The siglec may include siglecl2.
[0010] Preferred antibodies of the invention comprise one or more variant CDRs set forth in the following Table A:
[0011] Each of the sequences in the table are listed separately below with its unique SEQ ID
[0012] NO.
[0013] More preferably, the antibodies have each of the CDRs associated with a specific clone. Preferably the antibody is not the MABL57 (WT) antibody or possess all six CDRs of the the MABL57 (WT) antibody.
[0014] More preferably, the light chain comprises the sequence:
[0015] EIVLTQSPATLSLSPGERATLSCXAXXSVXXFLXWYQQKPGQAPRLLIFXXSNRAXGI
[0016] PARFSGSGSGTDFTLTISSLEPEDFAVYYCXQRSNWITFGQGTRLE / 7?7,E4A 5FF /
[0017] FPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO. 327)
[0018] Where the CDRs are indicated in bold; the Kappa sequence is shown in italics; CDR1, XAXXSVXXFLX, (SEQ ID NO. 328); is selected from:
[0019] (i) RASQSVSSFLA (SEQ ID NO. 329);
[0020] (ii) KASHSVSSFLS (SEQ ID NO. 330);
[0021] (iii) RASQSVSSFLS (SEQ ID NO. 331);
[0022] (iv) RASHSVSSFLS (SEQ ID NO. 332);
[0023] (v) KASQSVSSFLS (SEQ ID NO. 333); or
[0024] (vi) TASQSVSSFLS (SEQ ID NO. 334);
[0025] CDR2, XXSNRAX (SEQ ID NO. 335), is selected from: (i) DASNRAT (SEQ ID NO. 336);
[0026] (ii) DASNRAN (SEQ ID NO. 337);
[0027] (iii) YTSNRAT (SEQ ID NO. 338); or
[0028] (iv) DTSNRAT (SEQ ID NO. 339);
[0029] CDR3, XQRSNWIT (SEQ ID NO. 340); is selected from:
[0030] (i) QQRSNWIT (SEQ ID NO. 341); or
[0031] (ii) HQRSNWIT (SEQ ID NO. 342);
[0032] More preferably, the heavy chain comprises the sequence:
[0033] QGQLVQSGAEVKKPGASVKVSCKASGYTFNXYXISWVRQAPGQGLEWMGWISAY NGFTXSTQKFXXRVTLTTDTSTSTAHMELRSLRSDDTAAYYCARXXXDGFDPWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCADA HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO. 343)
[0034] Where the CDRs are indicated in bold; the G1 constant sequence is shown in italics;
[0035] CDR1, NXYXIS (SEQ ID NO. 344); is selected from:
[0036] (i) NNYGIS (SEQ ID NO. 345);
[0037] (ii) NSYGIS (SEQ ID NO. 346); or
[0038] (ii) NKYGIS (SEQ ID NO. 347);
[0039] CDR2, WISAYNGFTXSTQKFXX (SEQ ID NO. 348); is selected from:
[0040] (i) WISAYNGFTRSTQKFQG (SEQ ID NO. 349); or
[0041] (ii) WISAYNGFTRSTQKFNG (SEQ ID NO. 350);
[0042] CDR3, XXXDGFDP (SEQ ID NO. 351); is:
[0043] (i) DGGDGFDP (SEQ ID NO. 352).
[0044] More preferably, the antibodies have each of the CDRs associated with a specific clone set forth in Table A. Preferably the antibody is not the MABL57 (WT) antibody or possess all six CDRs of the the MABL57 (WT) antibody.
[0045] The antibody may include at least one complementarity determining region (CDR) amino acid sequence selected from Table 5, at least one variable domain comprising a CDR amino acid sequence set selected from Table 6, and / or a pair of variable domains comprising a CDR amino acid sequence set pair selected from Table 7. The antibody may include at least one antibody framework (FR) amino acid sequence selected from Table 8. The antibody may include a variable domain amino acid sequence selected from Table 2 or encoded by a nucleic acid sequence selected from Table 3. The antibody may include a variable domain amino acid sequence pair selected from Table 4.
[0046] The antibody may bind to the siglecl2 extracellular domain. The antibody may bind to the siglecl2 long isoform extracellular domain, the siglecl2 short isoform extracellular domain, a subdomain of the siglecl2 long isoform extracellular domain, and / or a subdomain of the siglecl2 short isoform extracellular domain. The subdomain of the siglecl2 long isoform extracellular domain and / or the subdomain of the siglecl2 short isoform extracellular domain may include the Vsetl (S12-V1) region, the Vset2 (S12-V2) region, the C2setl (S 12- Cl) region, or the C2set2 (S12-C2) region. The antibody may bind to a combination of subdomains of the siglecl2 extracellular domain. The combination of subdomains may include S12-V2 and S12-C1 (S12-V2C1) or S12-V2, S12-C1, and S12-C2 (S12-V2C1C2). The antibody may not bind to S12-V1 or S12-C2. The antibody may not bind to siglec7 or siglec9. The antibody may not bind to any siglec proteins other than siglecl2. The siglec may be associated with a cell. The cell may be a cancer cell. The cancer cell may be from a cancer selected from any of those listed in Table 10. The cancer cell may be a leukemia cell. The leukemia cell may be an acute myeloid leukemia (AML) cell or a chronic myeloid leukemia (CML) cell. Antibody binding to cell-associated siglec may induce cell death. Antibody binding to cell-associate siglec may inhibit tumor immunosuppression. Antibody binding to cell-associated siglec may induce antibody-dependent cellular cytotoxicity (ADCC). Antibody binding to cell-associated siglec may induce complement-dependent cytotoxicity (CDC). The antibody may be a bispecific antibody. The antibody may include a CD3 binding domain. The antibody may include a chimeric antigen receptor. The antibody may include a conjugate. The conjugate may include a therapeutic agent. The therapeutic agent may include a toxin. The conjugate may include a detectable label.
[0047] The antibody may include a variable domain amino acid sequence pair which includes a variable heavy chain sequence of SEQ ID NO: 4 and a variable light chain sequence of SEQ ID NO: 11. The variable heavy chain sequence of SEQ ID NO: 4 may include: a CDR1 sequence of SEQ ID NO: 32 including one or more substitutions as indicated in Table 29A, a CDR2 sequence of SEQ ID NO: 38 including one or more substitutions as indicated in Table 29 A, and a CDR3 sequence of SED ID NO: 44 including one or more substitutions as indicated in Table 29A; and wherein the variable light chain sequence of SEQ ID NO: 11 includes: a CDR1 sequence of SEQ ID NO: 51 including one or more substitutions as indicated in Table 29B, a CDR2 sequence of SEQ ID NO: 57 including one or more substitutions as indicated in Table 29B, and a CDR3 sequence of SEQ ID NO: 63 including one or more substitutions as indicated in Table 29B. The variable heavy chain sequence of SEQ ID NO: 4 may include: a CDR1 sequence of SEQ ID NO: 32 including one or more substitutions as indicated in Table 39A, a CDR2 sequence of SEQ ID NO: 38 including one or more substitutions as indicated in Table 39A, and a CDR3 sequence of SED ID NO: 44 including one or more substitutions as indicated in Table 39A; and wherein the variable light chain sequence of SEQ ID NO: 11 includes: a CDR1 sequence of SEQ ID NO: 51 including one or more substitutions as indicated in Table 39B, a CDR2 sequence of SEQ ID NO: 57 including one or more substitutions as indicated in Table 39B, and a CDR3 sequence of SEQ ID NO: 63 including one or more substitutions as indicated in Table 39B.
[0048] In some embodiments, the present disclosure provides a method of treating a therapeutic indication in a subject using an antibody that binds a siglec and includes at least one human variable domain. The therapeutic indication may include a cancer-related indication. The cancer-related indication may include leukemia. The leukemia may include AML and / or CML. The AML and / or CML may include cancer cells expressing siglec!2. The antibody may be administered to the subject. The antibody may be administered to the subject by injection or infusion.
[0049] In some embodiments, the present disclosure provides a method of detecting a siglec in a subject or a subject sample by contacting the subject or subject sample with an antibody that binds a siglec and includes at least one human variable domain. The antibody may include a detectable label. The antibody may bind to the siglec in the subject or subject sample and a detection reagent may be used to detect the bound antibody. The method may include detecting the siglec in a subject sample that includes a cell. The siglec may be detected in the subject sample by fluorescence-associated cell sorting (FACS) analysis. The siglec may be detected in the subject sample by immunohistochemistry. The immunohistochemistry may involve a colorimetric-based system or an immunofluorescencebased system for siglec detection.
[0050] In some embodiments, the present disclosure provides a method of stratifying subjects based on detection of a siglec in the subject or a subject sample by detecting a siglec in the subject or the subject sample according to any of the methods described herein and classifying the subject according to the type and / or level of siglec detected. The subject may be classified according to the presence or absence of siglec!2 and / or level of siglec!2 in the subject or the subject sample. The subject may be further classified according to the presence or absence of a specific siglecl2 extracellular subdomain and / or level of the specific siglecl2 extracellular subdomain in the subject or the subject sample.
[0051] In some embodiments, the present disclosure provides a method of treating a subject with cancer by administering an anti-siglecl2 antibody to the subject, the anti-siglecl2 antibody including: a heavy chain variable domain (VH) including an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-7; and a light chain variable domain (VL) including an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-14. The anti-siglecl2 antibody may bind a subject cancer cell. The subject cancer cell may be an AML cancer cell. The anti-siglecl2 antibody may be internalized by the subject cancer cell. The anti-siglecl2 antibody may be conjugated to a cytotoxin. The cytotoxin may include calicheamicin. The cytotoxin may be MYLOTARG®. The VH may include the amino acid sequence of SEQ ID NO: 4 and the VL may include the amino acid sequence of SEQ ID NO: 11. The anti-siglecl2 antibody may include a format selected from the group consisting of a Fab format and a whole antibody format. The equilibrium dissociation constant (Kd) for binding of the anti-siglecl2 antibody to siglecl2 may be from about 1 nM to about 10 nM.
[0052] BRIEF DESCRIPTION OF THE FIGURES
[0053] The foregoing and other objects, features and advantages of particular embodiments of the disclosure will be apparent from the following description and illustrations in the accompanying figures.
[0054] Fig. 1 is a graph showing differential expression levels of siglecl2 mRNA between normal tissue and tumors originating in the same tissue. RNA-seq measured gene expression is expressed in RSEM units (RNA-sequencing by Expectation Maximization).
[0055] Fig. 2 is a graph showing siglecl2 mRNA transcript levels in various cancer cell lines measured by RNA-seq. mRNA level is expressed in TPM (Transcript Per kilobase Million).
[0056] Fig. 3 is a graph showing median siglecl2 mRNA expression levels in various hematopoietic and lymphoid tissue cancer cell lines. RNA-seq measured gene expression is expressed as TPM.
[0057] Fig. 4 is a graph showing mRNA expression levels of different acute myeloid leukemia cell antigens in acute myeloid leukemia cell lines. RNA-seq measured gene expression is expressed in TPM.
[0058] Fig. 5 is a graph showing mRNA expression levels of different acute myeloid leukemia cell antigens in hematopoietic cells. RNA-seq measured gene expression is expressed in TPM. Fig. 6 is a graph showing mRNA expression levels of different acute myeloid leukemia cell antigens in hematopoietic progenitor and stem cells. RNA-seq measured gene expression is expressed in TPM.
[0059] Fig. 7 is a graph comparing siglecl2 and CD33 mRNA expression levels in various normal tissues. RNA-seq measured gene expression is expressed as median TPM.
[0060] DETAILED DESCRIPTION
[0061] In some embodiments, the present disclosure provides antibodies that bind sialic acid binding-immunoglobulin type lectins (siglecs). Siglecs are a large family of proteins with fifteen members. They contain an N terminal V set immunoglobulin domain that binds to sialic acid glycans found on N-linked glycans and glycolipids (Duan and Paulson., 2020, Ann Rev Immunology 14, 365-395). The extracellular domains also consist of 1-16 C set immunoglobulin (Ig) domains. These Ig V set and C set domains are structurally similar to antibody variable and constant domains, respectively.
[0062] Siglec 1, 2, 4 and 15 are orthologues of one another. The remaining members of the siglec family are called CD33 related siglecs since they are thought to be derived from duplication of the CD33 gene. Sialic acids are nine carbon anionic sugars with a carboxyl group at Cl, an N-acetyl group at C5 and a glycerol side chain from C7-C9. The sialic acid binding sites in the V set domains of siglecs contain a conserved arginine residue that forms a salt bridge with the Cl carboxyl group of sialic acid.
[0063] The majority of siglecs contain immunoreceptor tyrosine inhibitor motifs within their intracellular domain including ITIM or ITIM-like motifs that can participate in inhibitory or activating signaling. ITIMs are phosphorylated by src kinases and recruit src-homology 2 domain (SH2) containing phosphatases SHP-1 and SHP-2. SHP-1 and SHP-2 dephosphorylate the signaling molecules in the activation complex and subsequently participate in a variety of signaling pathways to influence cellular activation. SHP2 is a known proto-oncogene that has been shown to promote tumor cell invasion, prevent tumor cell apoptosis and promote cellular proliferation.
[0064] Siglecl2 is comprised of two V set domains, two C set domains, a transmembrane domain, and two ITIM domains on the intracellular domain. Siglecl2 is unique in the siglec family for several reasons: 1) the protein has two amino-terminal V-set domains (Yu et al., 2001, J Biol Chem, 276, 23816-24), compared with only one in all other siglecs; 2) there is a human-universal mutation of critical arginine residues in both V-set domains, rendering it unable to form a salt bridge with the carboxylic acid at Cl of sialic acid; 3) the Arg — >Cys mutation of the V-set 1 domain is not present in orthologs of closely related “great apes” (chimpanzee, baboon, gorilla and orangutan) (Angata et al., 2001, J Biol Chem, 276, 40282- 7); 4) the siglecl2 gene harbors a common polymorphic frameshift mutation, causing early truncation of siglecl2 and loss of expression of the long isoform (Mitra et al., 2011, J Biol Chem, 286, 23003-11). In normal tissues siglecl2 is expressed in the spleen and more specifically, on tissue macrophages and monocytes. Unlike the other siglecs, siglecl2 is expressed on certain epithelial cell cancers such as prostate cancer (Mitra et al., 2011, J Biol Chem, 286, 23003-11).
[0065] Siglecl2 was originally cloned in 2001 and shown to have two isoforms derived from alternative splicing (Foussias et al., 2001, BBRC 284, 887-899). The spliced form removes the first exon generating a short isoform of 455 amino acids that lacks the first V set domain (Flores et al. 2019, Cell Mol Immunology, 16, 154-164). This is particularly relevant because the polymorphic frameshift mutation is in the first exon that causes premature termination of the protein. This frameshift mutation is present in 50-60% of the human population. However, because of the alternatively spliced isoform (short isoform), one or both isoforms is (are) expressed throughout the population so no null alleles exist in the population.
[0066] Similar to other siglecs, siglecl2 has ITIM signaling domains intracellularly. Despite loss of its canonical sialic acid binding site, siglecl2 has been demonstrated to recruit SHP1 and SHP2 to the proximal ITIM domain (Yu et al., J Biol Chem, 276, 23816-23824). While siglecl2 in humans has lost the ability to form a salt bridge with the sialic acid carboxylic acid, it still retains key conserved residues that interact with sialic acids, namely two aromatic residues that form van der Waals contact with sialic acid in both V set domains (Tyr24 and Trpl30) and the second V set domain (Tyrl51 and Trp257). The sialic acid dependent binding data to date is controversial and based on sialic acid dependent red blood cell resetting (Yu et al., J Biol Chem, 276, 23816-23824, Angata et al., 2001, J Biol Chem, 276, 40282-7).
[0067] I. Compounds and compositions
[0068] In some embodiments, the present disclosure provides compositions that interact with cell surface proteins. Such compositions may be antibodies that bind siglecs, referred to herein as “anti-siglec antibodies.” Anti-siglec antibodies may be useful for treating and / or diagnosing subjects, as well as other applications described herein. Antibodies
[0069] In some embodiments, the present disclosure provides antibodies (e.g., anti-siglec antibodies). As used herein, the term “antibody” is used in the broadest sense and specifically covers numerous embodiments, including, but not limited to, polyclonal antibodies, monoclonal antibodies, multispecific antibodies (e.g., bispecific antibodies or trispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, single chain antibodies, single chain Fv (scFv) formats, diabodies, intrabodies, unibodies, maxibodies, chimeric antigen receptors (CARs), and antibody fragments. As used herein the term “antibody fragment” refers to a portion of a whole antibody or a fusion protein that includes such a portion. Antibody fragments may include antigen binding regions. In some embodiments, antibody fragments include, but are not limited to Fab fragments, Fab’ fragments, F(ab’)2 fragments, Fv fragments, Fc fragments, variable domains, constant domains, heavy chains, and light chains. In some embodiments, antibody fragments may be prepared by enzymatic digestion. Fab fragments may be prepared by papain digestion of whole antibodies. F(ab’)2 fragments may be prepared by pepsin treatment of whole antibodies.
[0070] "Native antibodies" refer to heterotetrameric glycoproteins having two identical light (L) chains and two identical heavy (H) chains. Genes encoding antibody heavy and light chains have been well characterized (see Matsuda, F. et al., 1998. The Journal of Experimental Medicine. 188(11); 2151-62 and Li, A. et al., 2004. Blood. 103(12): 4602-9, the content of each of which are herein incorporated by reference in their entirety). Light chains are linked to heavy chains by a covalent disulfide bond, while the number of disulfide linkages between heavy chains differs among immunoglobulin isotypes. Each heavy chain includes a variable domain (VH) followed by a number of constant domains. Light chains include a variable domain (VL) at one end and a constant domain at the other.
[0071] As used herein, the term "variable domain" refers to specific antibody domains found on both the antibody heavy and light chains that differ extensively in sequence among antibodies and determine antibody specificity for particular antigens. Variable domains include hypervariable regions that include amino acid residues responsible for antigen binding. Amino acids present within hypervariable regions determine the structure of complementarity determining regions (CDRs) that become part of the antigen-binding site of the antibody. As used herein, the term “CDR” refers to an antibody region having a structure that is complimentary to its target antigen or epitope. Other portions of variable domains, not interacting with antigen, are referred to as “framework regions” (FRs). Antigen-binding sites (also known paratopes) include amino acid residues necessary for interacting with particular antigens. Residues making up antigen-binding sites may be determined by CDR analysis. As used herein, “CDR analysis” refers to a process for determining which antibody variable domain amino acids form CDRs. Various methods of determining CDR sequences are known in the art and may be applied to known antibody sequences (Strohl, W.R. Therapeutic Antibody Engineering. Woodhead Publishing, Philadelphia PA. 2012. Ch. 3, p47-54, the contents of which are herein incorporated by reference in their entirety). CDR analysis may be carried out by co-crystallography with bound antigen. In some embodiments, CDR analysis includes computational assessments based on alignment with other antibodies (Strohl, W.R. Therapeutic Antibody Engineering. Woodhead Publishing, Philadelphia PA. 2012. Ch. 3, p47-54, the contents of which are herein incorporated by reference in their entirety). CDR analysis may utilize numbering schemes including, but not limited to, those described by Kabat [Wu, T.T. et al., 1970, JEM, 132(2):211-50 and Johnson, G. et al., 2000, Nucleic Acids Res. 28(1): 214-8, the contents of each of which are herein incorporated by reference in their entirety], Chothia [Chothia and Lesk, J. Mol. Biol. 196, 901 (1987), Chothia et al., Nature 342, 877 (1989), and Al-Lazikani, B. et al., 1997, J. Mol. Biol. 273(4):927-48, the contents of each of which are herein incorporated by reference in their entirety], Lefranc (Lefranc, M.P. et al., 2005, Immunome Res. 1:3), and Honegger (Honegger, A. and Pluckthun, A. 2001. J. Mol. Biol. 309(3):657-70, the contents of which are herein incorporated by reference in their entirety).
[0072] VH and VL domains each include three CDRs. VL CDRs are referred to herein as CDRL1, CDRL2 and CDRL3, in order of occurrence along the VL fromN- to C- terminus. VH CDRs are referred to herein as CDRH1, CDRH2 and CDRH3, in order of occurrence along the VH from N- to C- terminus. Most CDRs have favored canonical structures except CDRH3, which includes amino acid sequences with high variability in sequence and length among antibodies resulting in varying three-dimensional antigen-binding domain structures (Nikoloudis, D. et al., 2014. PeerJ. 2:e456).
[0073] VH and VL domains have four framework regions (FRs) each positioned before, after, and between CDR regions. VH framework regions are referred to herein as FRH1, FRH2, FRH3, and FRH4 and VL framework regions are referred to herein as FRL1, FRL2, FRL3, and FRL4. FRs and CDRs of VH domains are typically in the order of FRH1-CDRH1- FRH2-CDRH2-FRH3-CDRH3-FRH4, fromN- to C-terminus. FRs and CDRs ofVL domains are typically in the order of FRL1-CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4, fromN- to C -terminus.
[0074] “Fv” antibody fragments include the minimum antibody fragment needed to form a complete antigen-binding site. These regions include a heavy chain and light chain variable domain dimer in tight, non-covalent association. Stable Fv fragments may be synthesized recombinantly through incorporation of a flexible linker between light and heavy chain variable domains to form single chain Fv (scFv) formats. Other Fv formats may include a disulfide bridge between heavy and light chain variable domains (Strohl, W.R. Therapeutic Antibody Engineering. Woodhead Publishing, Philadelphia PA. 2012. Ch. 3, p46-47, the contents of which are herein incorporated by reference in their entirety).
[0075] Vertebrate antibody light chains typically fall into one of two distinct types, kappa and lambda based on constant domain amino acid sequence. Additional antibody classes depend on heavy chain constant domain amino acid sequences.
[0076] ScFvs may be utilized in conjunction with phage display, yeast display or other display technologies to create scFv libraries expressed in association with cell or coat surfaces (e.g. in association with phage coat proteins) for identification of peptides with high antigen affinity. Antibodies may be prepared as scFvFc antibodies which include fusions of scFvs with antibody Fc domains.
[0077] “Chimeric antibodies” refer to antibodies with portions derived from two or more sources, e.g., from different species. Chimeric antibodies may include mouse variable domains and human constant domains. Examples of chimeric antibodies and related methods of synthesis are described in United States Patent Numbers 5,807,715; 4,816,567; and 4,816,397, the contents of each of which are incorporated herein by reference in their entirety.
[0078] “Chimeric antigen receptors” or “CARs” refer to artificial receptors engineered for expression on immune effector cell surfaces facilitating specific targeting of such immune effector cells to cells expressing CAR target antigens. CARs may be designed to include one or more antibody segments, e.g., antibody variable domains and / or antibody CDRs, to direct immune effector cells to antigens recognized by such antibody segments. In some cases, CARs are designed to specifically target cancer cells, leading to immune-mediated clearance of the cancer cells.
[0079] The term "monoclonal antibody" refers to an antibody obtained from a substantially homogeneous cell population producing substantially identical antibodies binding to the same epitope of a specific target antigen. “Polyclonal” antibody preparations typically include a heterogeneous group of antibodies directed against different epitopes of a specific target.
[0080] Monoclonal antibodies may be prepared using a number of different methods. Monoclonal antibodies may be chimeric with portions derived from two or more species. For example, chimeric monoclonal antibodies may include antibody variable domains corresponding with human variable domain sequences and antibody constant domains corresponding with mouse constant domain sequences.
[0081] Antibodies of the present disclosure may be derived from or correspond with antibodies of different animal origins including mammals, birds, reptiles, and insects. Mammalian antibodies may be, for example, of murine (e.g., mouse or rat), rabbit, donkey, sheep, goat, guinea pig, camel, bovine, horse, or human origin.
[0082] As used herein, the term “antibody variant” refers to a biomolecule resembling an antibody in structure, sequence and / or function, but including some differences in their amino acid sequence, composition or structure as compared to another antibody or a native antibody.
[0083] Antibodies of the present disclosure may include a conjugate. As used herein, the term “conjugate” refers to any agent, cargo, or chemical moiety attached to a recipient compound or the process of attaching such an agent, cargo, or chemical moiety. As used herein, the term “antibody conjugate” refers to an antibody having an attached agent, cargo, or chemical moiety. Conjugates may include therapeutic agents. Therapeutic agents may include drugs. Antibody conjugates that include conjugated drugs are referred to herein as “antibody drug conjugates.” Antibody drug conjugates may be used to deliver conjugated drugs to specific targets based on antibody affinity for specific proteins or epitopes. Antibody drug conjugates may be used to focus biological activity of conjugated drugs to targeted cells, tissues, organs, etc.
[0084] In some embodiments, antibody conjugates include detectable labels. Detectable labels may be used to detect antibody binding. Examples of detectable labels include, but are not limited to, radioisotopes, fluorophores, chromophores, chemiluminescent compounds, enzymes, enzyme co-factors, dyes, metal ions, ligands, biotin, avidin, streptavidin, haptens, quantum dots, or any other detectable labels known in the art or described herein.
[0085] Conjugates may be attached directly or via a linker. Direct attachment may involve covalent bonding or non-covalent associations (e.g., ionic bonds, hydrostatic bonds, hydrophobic bonds, hydrogen bonds, hybridization, etc.). Linkers used for conjugation may include any chemical structures capable of joining antibodies with conjugates. For example, linkers may include polymeric molecules (e.g., nucleic acids, polypeptides, polyethylene glycols, carbohydrates, lipids, or combinations thereof). Antibody conjugate linkers may be cleavable (e.g., through contact with an enzyme, change in pH, or change in temperature).
[0086] Antigens
[0087] Antibodies may be developed (e.g., through immunization) or selected (e.g., from pool of candidates), for example, using antigens. An “antigen,” as referred to herein, is any entity that induces an immune response in an organism or may simply refer to an antibody binding partner. Immune responses are reactions of cells, tissues and / or organs of an organism to a foreign entity. Immune responses typically lead to the production of one or more antibodies against a foreign entity by an organism.
[0088] In some embodiments, antigens of the present disclosure include siglecs or portions thereof, referred to herein as “siglec antigens.” Siglec antigens may include siglec extracellular domains. Siglec antigens may include fusion proteins of siglecs or siglec portions with other entities. In some embodiments, siglec antigens include fusion proteins of siglec extracellular domains with antibody Fc regions. Fc regions used in siglec antigen fusion proteins may be derived from different species.
[0089] As used herein, the term “target antigen” refers to an entity, protein, or epitope to which an antibody binds or for which an antibody is desired, designed, or developed to have affinity for.
[0090] Immunization
[0091] In some embodiments, antibodies may be prepared by immunization. Immunization may include immunizing a host with the target antigen of an antibody being developed. Host animals (e.g. mice, rabbits, goats, primates, or llamas) may be utilized for immunizations to elicit lymphocytes specific for a target antigen. Lymphocytes may be isolated and fused with immortalized cell lines to yield hybridomas which can be cultured and propagated (e.g., see Kohler, G. et al., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495-7, the contents of which are herein incorporated by reference in their entirety). In some embodiments, lymphocyte immunization may be carried out in vitro.
[0092] Immortalized cell lines used for hybridoma generation may be transformed mammalian cells (e.g., myeloma cells of rodent, rabbit, bovine, or human origin). Rat or mouse myeloma cell lines may be employed. Hybridoma cells may be cultured with one or more substances that inhibit growth or survival of unfused cells. In some embodiments, culture media supplemented with hypoxanthine, aminopterin, and thymidine ("HAT medium") may be used to culture hybridoma cells generated from parental cells lacking hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT) to prevent growth of HGPRT-deficient (unfused) cells.
[0093] In some embodiments, immortalized cell lines are murine myeloma lines. Human myeloma and mouse-human heteromyeloma cell lines may be used for preparation of human monoclonal antibodies (e.g., see Kozbor, D. et al., A human hybrid myeloma for production of human monoclonal antibodies. J Immunol. 1984 Dec;133(6):3001-5 and Brodeur, B. et al., Monoclonal Antibody Production Techniques and Applications. Marcel Dekker, Inc., New York. 1987; 33:51-63, the contents of each of which are herein incorporated by reference in their entireties).
[0094] Media from hybridoma cell cultures may be assayed for secreted antibodies with desired specificity. Such assays may include, but are not limited to, enzyme-linked immunosorbent assays (ELISA) and fluorescence-associated cell sorting (FACS) assays. Assays may be carried out to determine binding specificity for target antigens. Hybridoma cells producing antibodies with desirable characteristics may be subcloned and expanded using standard methods. Hybridoma antibodies may be isolated and purified using standard immunoglobulin purification procedures, e.g., protein A-SEPHAROSE® purification, hydroxyapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. Hybridoma cells may be grown in vivo in mammals as ascites. In some embodiments, antibodies may be isolated directly from host serum samples.
[0095] In some embodiments, antibodies generated through immunization may be analyzed for amino acid sequence or encoding nucleic acid sequence for reproduction using recombinant technology. For example, antibodies may be produced by insertion of nucleic acid sequences encoding antibodies into expression vectors for introduction into cells and expression of encoded antibodies.
[0096] Anti-siglec antibodies
[0097] In some embodiments, the present disclosure provides anti-siglec antibodies. The antibodies may bind to siglec!2. In some embodiments, anti-siglec antibodies of the present disclosure include any of the antibodies listed in Table 1. Table 1. Anti- siglec antibodies
[0098] Antibodies may bind siglecl2 extracellular domains. Such siglecl2 extracellular domains may include long isoforms or short isoforms. In some embodiments, antibodies of the present disclosure bind a subdomain of the siglecl2 extracellular domain (long or short isoform). Such subdomains may include the siglecl2 Vsetl (S12-V1) region, the Vset2 (S12- V2) region, the C2setl (S12-C1) region, or the C2set2 (S12-C2) region. Antibodies may bind to combinations of subdomains. Combinations may include S12-V2 and S12-C1 (S 12- V2C1). In some embodiments, combinations may include S12-V2, S12-C1, and S12-C2 (S12-V2C1C2), which correspond with siglec!2 short isoform extracellular domains. Anti-siglec antibodies binding to S12-V2C1 may be used to target and / or detect both long and short siglec!2 isoforms. Such antibodies may be useful for targeting cells expressing both long and short siglec!2 isoforms. In some embodiments, antibodies binding to S12- V2C1 may not bind to S12-V1 or S12-C2 or may bind to either with reduced affinity in comparison to affinity for S12-V2C1.
[0099] In some embodiments, antibodies of the present disclosure bind to S12-C2. S12-C2 is located on a region of the siglecl2 extracellular domain that is closer to the cell surface. Binding to epitopes close to the cell surface has been shown to provide greater sensitivity with respect to cell cytotoxicity with anti-CD3 bispecific antibody treatments (e.g., see Estey E.H. et al., Am J Hematol. 2018. 93:1267-91). Accordingly, anti-siglec antibodies described herein that bind to S12-C2 may be utilized to produce bispecific antibodies with both a siglec binding region and a CD3 binding region.
[0100] In some embodiments, antibodies binding to siglecl2 may not bind to other siglecs, including other siglecs of the CD33-related siglec family (e.g., siglec7 or siglec9, which have the greatest sequence identity to siglecl2).
[0101] Anti-siglec antibodies may bind siglecs associated with cells (e.g., cell surfaces). Such cells may include cancer cells. Cancer cells bound by anti-siglec antibodies (e.g., anti- siglecl2 antibodies) may be leukemia cells. Such leukemia cells may include, but are not limited to, acute myeloid leukemia (AML) cells and chronic myeloid leukemia (CML) cells.
[0102] In some embodiments, anti-siglec antibodies of the present disclosure may include at least one human antibody variable domain. Such antibodies may be prepared through immunization of hosts expressing antibody variable domains corresponding with human antibody variable domains. Hosts expressing variable domains corresponding with human variable domains may include Trianni transgenic mice (e.g., see United States Publication Number US2013 / 0219535, the contents of which are herein incorporated by reference in their entirety). Endogenous immunoglobulin VH, DH and JH; VK and JK; and VZ and JZ gene segments have been replaced in these mice by the full repertoire of human counterpart gene segments. Human gene coding sequences are flanked by mouse cis-acting regulatory elements and recombination signal sequences allowing for a “normal” immune response, including isotype switching with heavy and light chain affinity maturation. The resulting human-mouse chimera antibodies contain human antibody variable domains flanked by mouse heavy and light chain immunoglobulin constant regions. These antibodies are more readily converted to fully human antibodies using standard methods to combine the human variable domains with human constant regions.
[0103] In some embodiments, anti-siglec antibodies of the present disclosure induce cell death upon binding to cell-associated siglecs. Such antibodies may induce antibody- dependent cellular cytotoxicity (ADCC) upon binding to siglec-associated cells. Antibody binding to cell-associated siglecs may induce complement-dependent cytotoxicity (CDC).
[0104] In some embodiments, anti-siglec antibodies of the present disclosure may inhibit tumor immunosuppression upon binding to cell-associated siglecs. Tumor immunosuppression involves dysfunctional suppression of anti-tumor immune responses. Anti-siglec antibodies may target cells involved in anti-tumor immunosuppression and inhibit their suppressive activities.
[0105] In some embodiments, anti-siglec antibodies (e.g., anti-siglecl2 antibodies) of the present disclosure may be used to develop or be incorporated into bispecific antibodies. Such antibodies may include a CD3 binding domain to recruit CD3 -expressing immune cells to cells expressing siglecs (e.g., siglecl2).
[0106] In some embodiments, anti-siglec antibodies (e.g., anti-siglecl2 antibodies) of the present disclosure may be used to develop or be incorporated into chimeric antigen receptors (CARs). Such CARs may be expressed on the surface of immune cells and facilitate recruitment of the immune cells to cells expressing siglecs (e.g., siglecl2).
[0107] In some embodiments, anti-siglec antibodies (e.g., anti-siglecl2 antibodies) of the present disclosure may include conjugates. Conjugates may include therapeutic agents. In some embodiments, therapeutic agents may include toxins. Such toxins may include, but are not limited to, radioisotopes, saporins, taxanes, vinca alkaloids, anthracy clines, calicheamicins, duocarmycins, pyrrolobenzodiazepine dimers, and platinum-based agents. Calicheamicins may include MYLOTARG®. In some embodiments, conjugates may include detectable labels.
[0108] Anti-siglec antibodies of the present disclosure may include variable domain amino acid sequences according to any of those listed in Table 2. In some embodiments, anti-siglec antibody variable domains include fragments or variants of variable domain amino acid sequences listed. Such fragments or variants may include from about 50% to about 99.9% sequence identity (e.g. from about 50% to about 60%, from about 55% to about 65%, from about 60% to about 70%, from about 65% to about 75%, from about 70% to about 80%, from about 75% to about 85%, from about 80% to about 90%, from about 85% to about 95%, from about 90% to about 99.9%, from about 95% to about 99.9%, about 97%, about 97.5%, about 98%, about 98.5%, about 99%, about 99.5%, about 99.6%, about 99.7% or about 99.8%) with one or more of the variable domain amino acid sequences listed in Table 2. Table 2. Variable domain amino acid sequences
[0109] Anti-siglec antibody variable domains of the present disclosure may be encoded by nucleic acid sequences listed in Table 3. In some embodiments, nucleic acid sequences encoding anti-siglec antibody variable domains of the present disclosure may include fragments or variants of the nucleic acid sequences listed. Such fragments or variants may include from about 50% to about 99.9% sequence identity (e.g. from about 50% to about 60%, from about 55% to about 65%, from about 60% to about 70%, from about 65% to about 75%, from about 70% to about 80%, from about 75% to about 85%, from about 80% to about 90%, from about 85% to about 95%, from about 90% to about 99.9%, from about 95% to about 99.9%, about 97%, about 97.5%, about 98%, about 98.5%, about 99%, about 99.5%, about 99.6%, about 99.7% or about 99.8%) with one or more of the nucleic acid sequences listed. In some embodiments, nucleic acid sequences encoding anti-siglec antibody variable domains of the present disclosure include codon-optimized variants of the nucleic acid sequences listed.
[0110] Table 3. Variable domain nucleic acid sequences
[0111] In some embodiments, anti-siglec antibodies of the present disclosure include VH and VL domain pairs, wherein each member of the pair includes a variable domain amino acid sequence presented herein and / or is encoded by a variable domain nucleic acid sequence presented herein. In some embodiments, anti-siglec antibodies of the present disclosure include a variable domain pair according to any of those listed in Table 4.
[0112] Table 4. Variable domain pairs
[0113] In some embodiments, anti-siglec antibodies of the present disclosure include one or more CDRs with amino acid sequences derived from one or more variable domain amino acid sequence provided in Table 2. In some embodiments, anti-siglec antibodies of the present disclosure include one or more CDRs encoded by nucleic acid sequences derived from one or more variable domain nucleic acid sequences provided in Table 3. Anti-siglec antibody CDRs may include one or more amino acid residues involved in antigen binding (e.g., as determined by co-crystallography with bound antigen). Anti-siglec antibodies of the present disclosure may include CDRs identified through CDR analysis of variable domain sequences presented herein via co-crystallography with bound antigen; by computational assessments based on comparisons with other antibodies (e.g., see Strohl, W.R. Therapeutic Antibody Engineering. Woodhead Publishing, Philadelphia PA. 2012. Ch. 3, p47-54); or Kabat, Chothia, Al-Lazikani, Lefranc, or Honegger numbering schemes, as described previously. In some embodiments, anti-siglec antibody CDR amino acid sequences may include any of those presented in Table 5, or fragments thereof. In some embodiments, anti- siglec antibodies of the present disclosure include CDRs that include amino acid sequence variants of those listed. Amino acid fragments or variants included in anti-siglec antibody CDRs may include from about 50% to about 99.9% sequence identity (e.g. from about 50% to about 60%, from about 55% to about 65%, from about 60% to about 70%, from about 65% to about 75%, from about 70% to about 80%, from about 75% to about 85%, from about 80% to about 90%, from about 85% to about 95%, from about 90% to about 99.9%, from about 95% to about 99.9%, about 97%, about 97.5%, about 98%, about 98.5%, about 99%, about 99.5%, about 99.6%, about 99.7% or about 99.8%) with one or more of the amino acid sequences listed.
[0114] Table 5. CDR amino acid sequences
[0115] In some embodiments, anti-siglec antibodies of the present disclosure include variable domains with a set of CDRs, wherein each member of the set includes a CDR amino acid sequence presented herein. In some embodiments, variable domain CDR amino acid sequence sets may include any of those presented in Table 6.
[0116] Table 6. Variable domain CDR amino acid sequence sets
[0117] In some embodiments, anti-siglec antibodies of the present disclosure include pairs of variable domain CDR amino acid sequence sets presented herein. In some embodiments, anti- siglec antibodies of the present disclosure include variable domain CDR amino acid sequence set pairs presented in Table 7.
[0118] Table 7. Variable domain CDR amino acid sequence set pairs
[0119] In some embodiments, anti-siglec antibodies of the present disclosure include one or more framework regions (FRs). FRs may include amino acid sequences derived from variable domain amino acid sequences provided in Table 2. FRs may be encoded by nucleic acid sequences derived from one or more variable domain nucleic acid sequences provided in Table 3. In some embodiments, anti-siglec antibody FRs may include amino acid sequences according to any of those presented in Table 8, or fragments thereof. In some embodiments, anti-siglec antibodies of the present disclosure include FRs that include amino acid sequence variants of those listed. Amino acid fragments or variants included in anti-siglec antibody FRs may include from about 50% to about 99.9% sequence identity (e.g. from about 50% to about 60%, from about 55% to about 65%, from about 60% to about 70%, from about 65% to about 75%, from about 70% to about 80%, from about 75% to about 85%, from about 80% to about 90%, from about 85% to about 95%, from about 90% to about 99.9%, from about 95% to about 99.9%, about 97%, about 97.5%, about 98%, about 98.5%, about 99%, about 99.5%, about 99.6%, about 99.7% or about 99.8%) with one or more of the amino acid sequences listed.
[0120] Table 8. FR amino acid sequences
[0121] Anti-siglec antibodies according to the present disclosure may be prepared using any of the antibody sequences (e.g., variable domain amino acid sequences, variable domain amino acid sequence pairs, CDR amino acid sequences, variable domain CDR amino acid sequence sets, variable domain CDR amino acid sequence set pairs, and / or framework region amino acid sequences) presented herein, any may be prepared, for example, as monoclonal antibodies, multispecific antibodies, chimeric antibodies, antibody mimetics, scFvs, or antibody fragments. In some embodiments, anti-siglec antibodies using any of the antibody sequences presented herein may be prepared as IgA, IgD, IgE, IgG, or IgM antibodies. When prepared as mouse IgG antibodies, anti-siglec antibodies may be prepared as IgGl, IgG2a, IgG2b, or IgG3 isotypes. When prepared as human IgG antibodies, anti-siglec antibodies may be prepared as IgGl, IgG2, IgG3, or IgG4 isotypes. Anti-siglec antibodies prepared as human or humanized antibodies may include one or more human constant domains.
[0122] Siglec protein antigens
[0123] In some embodiments, anti-siglec antibodies bind to siglec!2 protein antigens. In some embodiments siglec!2 protein antigens include any of those listed in Table 9. Some siglec!2 proteins antigens may be post-translationally processed or recombinantly expressed to exclude leader sequences (underlined in the Table). In some embodiments, siglec!2 proteins may include variants or fragments of the sequences listed.
[0124] Table 9. SiglecH protein antigen sequences
[0125] In some embodiments, anti-siglec antibodies of the present disclosure bind to siglec!2 protein epitopes on siglec!2 protein antigens described herein. Such siglec!2 protein epitopes may include or be included within a siglecl2 protein antigen amino acid sequence listed in Table 9. In some embodiments, anti-siglec antibodies of the present disclosure bind to siglec!2 protein epitopes that include a region formed by a complex of a siglec!2 protein epitope with another protein or epitope.
[0126] In some embodiments, siglec!2 protein antigens may be prepared as fusion proteins. Siglecl2 protein antigens may be prepared as fusion proteins with antibody Fc regions. Fusions with antibody Fc regions may be prepared to facilitate immunization and generation of siglec!2 protein antigen-specific immune response. In some embodiments, siglect!2 protein antigens are prepared as fusion proteins with mouse Fc regions. Such Fc regions may include Fc2a fragment (UniProtKB PO1863.1, amino acids 98-330, PRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQI SWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPA PIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKT ELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSR TPGK, SEQ ID NO: 177) or may include mouse 2cFc (EPRVPITQNPCPPLKECPPCAAPDLLGGPSVFIFPPKIKDVLMISLSPMVTCVVVDVSE DDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKV NNRALPSPIEKTISKPRGPVRAPQVYVLPPPAEEMTKKEFSLTCMITGFLPAEIAVDWT SNGRTEQNYKNTATVLDSDGSYFMYSKLRVQKSTWERGSLFACSVVHEGLHNHLTT KTISRSLGK, SEQ ID NO: 178).
[0127] Mouse Fc regions may be used in place of human Fc when carrying out immunizations in mice to minimize generation of antibodies against Fc regions.
[0128] II. Methods
[0129] In some embodiments, the present disclosure provides methods of using and evaluating anti- siglec antibodies for therapeutic and diagnostic applications.
[0130] Therapeutic applications
[0131] In some embodiments, the present disclosure provides methods of treating therapeutic indications using anti-siglec antibodies (e.g., any of those described herein). The term “therapeutic indication,” as used herein, refers to any disease, symptom, condition, or disorder that may be alleviated, stabilized, improved, cured, or otherwise addressed by some form of treatment or other therapeutic intervention. In some embodiments, the present disclosure provides methods of treating therapeutic indications in subjects by providing antibodies disclosed herein.
[0132] As used herein the terms “treat,” “treatment,” and the like, refer to any actions taken to offer relief from or alleviation of pathological processes. As it relates to any of the therapeutic indications recited herein, the terms “treat,” “treatment,” and the like mean to relieve or alleviate at least one symptom associated with such indications, or to slow or reverse the progression or anticipated progression of such indications.
[0133] In some embodiments, the present disclosure provides methods of treating therapeutic indications in subjects using anti-siglec antibodies (e.g., any of the antibodies described herein). Such antibodies may include human variable domains. Therapeutic indications may include cancer-related indications, e.g., leukemia, e.g., AML and / or CML. The methods of treatment may include administering anti-siglec antibodies to subjects, e.g., by injection or infusion.
[0134] Cancer-related indications
[0135] In some embodiments, therapeutic indications include cancer-related indications. The term “cancer” refers to a collection of diseases characterized by dysfunctional cell growth and division, in some cases spreading between bodily regions. As used herein, the term “cancer-related indication” refers to any disease, disorder, or condition pertaining to cancer, cancer treatment, or pre-cancerous conditions. Cancer-related indications include, but are not limited to, pathological conditions characterized by malignant neoplastic growths, tumors, and / or hematological malignancies. In some embodiments, methods of the present disclosure include treatment of cancer-related indications with anti-siglec antibodies (e.g., any of those described herein).
[0136] Cancer-related indications include leukemias, which are cancers of the blood or blood forming tissues (e.g., bone marrow and lymphatic system). Leukemias are typically classified by progression and affected cell type. Acute leukemias develop quickly while chronic leukemias develop slowly with worsening effects over time. Lymphocytic leukemias affect lymphocytes, typically due to mutations in cells that make lymphocytes. Myelogenous leukemias involve myeloid cells responsible for blood cell production.
[0137] In some embodiments, methods of the present disclosure include treatment of acute myeloid leukemia (AML) and / or chronic myeloid leukemia (CML) with anti-siglec antibodies (e.g., any of those described herein). AML involves rapid abnormal myeloblast accumulation, typically in the bone marrow. CML involves mutation in immature myeloid cells leading to a more gradual accumulation of leukemia cells over time that can spread to other parts of the body.
[0138] Additional cancer-related indications include, but are not limited to, any of those listed in Table 10 below. Anti-siglec antibodies used according to cancer-related indication treatment methods described herein may bind to siglec!2 associated with cancer cells, including cancer cells associated with any of the cancer-related indications listed in Table 10.
[0139] Table 10. Cancer-related indications _
[0140] Anti-siglec antibodies used according to cancer-related indication treatment methods described herein may bind to siglecl2 associated with solid epithelial tumors. Such tumors have been shown by immunohistochemical analysis to express siglecl2 (United States Publication Number US2020 / 0003779). According to some methods, siglecl2-associated cancer cells targeted according to treatment methods of the present disclosure include hematopoietic cells and / or lymphoid cells.
[0141] In some embodiments, methods of the present disclosure include treatment of AML and / or CML in subjects by providing anti-siglec antibodies (e.g., any of the anti-siglec antibodies described herein). Siglec-3 or CD33 is expressed on AML cells, including AML blasts in AML patients. Gemtuzumab Ozogamicin (GO, MYLOTARG®, Pfizer, New York, NY) is an antibody drug conjugate that targets CD33 and includes a calicheamicin warhead. GO is the only currently listed form of immunotherapy for AML. In some embodiments, anti-siglec antibodies of the present disclosure target siglecl2 on AML and / or CML cells in subjects treated according to methods described herein.
[0142] In some embodiments, the present disclosure provides methods of treating subjects with cancer by administering an anti-siglecl2 antibodies (e.g., any of those described herein). The anti-siglecl2 antibodies may include VH amino acid sequences according to any of those presented in Table 2 and / or may be encoded by any of the nucleic acid sequences presented in Table 3. The anti-siglec 12 antibodies may include VL amino acid sequences according to any of those presented in Table 2 and / or may be encoded by any of the nucleic acid sequences presented in Table 3. The anti-siglecl2 antibodies may bind subject cancer cells. Such cancer cells may include AML cancer cells. In some embodiments, the anti-siglecl2 antibodies may be internalized by bound cells. Such antibodies may be ADCs. Therapeutic agents associated with such ADCs may include cytotoxins. Such toxins may include, but are not limited to, radioisotopes, saporins, taxanes, vinca alkaloids, anthracyclines, calicheamicins, duocarmycins, pyrrolobenzodiazepine dimers, and platinum-based agents. Calicheamicins may include MYLOTARG®. In some embodiments, the anti-siglecl2 antibodies include a VH with the amino acid sequence of SEQ ID NO: 4 and a VL with the amino acid sequence of SEQ ID NO: 11. The anti-siglecl2 antibodies may be whole antibodies or may be antibody fragments (e.g., Fab fragments). The anti-siglecl2 antibodies may have an equilibrium dissociation constant (Kd) for binding to siglecl2 of from about 0.001 nM to about 10,000 nM (e.g., from about 0.001 nM to about 0.1 nM, from about 0.01 nM to about 1 nM, from about 0.5 nM to about 5 nM, from about 1 nM to about 10 nM, from about 2 nM to about 20 nM, from about 5 nM to about 50 nM, from about 15 nM to about 100 nM, from about 25 nM to about 250 nM, from about 100 nM to about 1,000 nM, or from about 500 nM to about 10,000 nM).
[0143] Diagnostic applications
[0144] In some embodiments, the present disclosure provides diagnostic methods involving use of anti-siglec antibodies. Such methods may include detecting siglecs using anti-siglec antibodies (e.g., any of the antibodies described herein). Such methods may include contacting subjects or subject samples with anti-siglec antibodies (e.g., any of those described herein). The anti-siglec antibodies may bind siglecl2. The anti-siglec antibodies may include human variable domains. Antibodies used for detection methods may include a detectable label. Detection methods may include the use of detection reagents to detect bound antibodies. As used herein, the term “detection reagent” refers to any compound or substance used to visualize or otherwise observe an object (e.g., a bound antibody or detectable label) or event. Detection reagents may include secondary antibodies or other high affinity compounds (e.g., biotin or avidin) that bind to antibodies being detected or associated conjugates. Detection reagents may be or include substrates for detection of enzymatic detectable labels (e.g., associated with a primary or secondary antibody).
[0145] Diagnostic applications of the present disclosure may include detecting siglecs in subject samples that include cells. In some embodiment cell-associated siglecs may be detected. Cell-associated siglecs may be detected in subject samples by fluorescence- associated cell sorting (FACS) analysis. In some embodiments, siglecs may be detected in subject samples by immunohistochemistry. Such methods may include the use of colorimetric-based systems or immunofluorescence-based systems for siglec detection. In some embodiments, the present disclosure provides methods of stratifying subjects based on detection of siglecs in subjects or subject samples. Such methods may include detecting siglecs in subjects or subject samples according to any of the methods described herein (e.g., using anti-siglec antibodies) and classifying subjects according to type and / or level of siglecs detected. In some embodiments, subjects may be classified according to the presence or absence of siglecl2 and / or level of siglecl2 in subjects or subject samples. Subjects may be further classified according to the presence or absence of specific siglecl2 extracellular subdomains and / or levels of specific siglecl2 extracellular subdomains in subjects or subject samples. Classifications used in subject stratification may include, but are not limited to, classifications by disease type, disease prognosis or severity, suitability for treatment, and type of treatment most likely to be successful or appropriate.
[0146] III. Definitions
[0147] Associated with: As used herein, the terms “associated with,” “conjugated,” “linked,” “attached,” and “tethered,” when used with respect to two or more entities, means that the entities are physically associated or connected with one another, either directly or via one or more moieties that serve as linking agents, to form a structure that is sufficiently stable so that the entities remain physically associated, e.g., under working conditions, e.g., under physiological conditions. An “association” need not be through covalent chemical bonding and may include other forms of association or bonding sufficiently stable such that the “associated” entities remain physically associated, e.g., ionic or hydrogen bonding or a hybridization-based connectivity.
[0148] Epitope: As used herein, an “epitope” refers to a surface or region on one or more entities that is capable of interacting with an antibody or other binding biomolecule. For example, a protein epitope may contain one or more amino acids and / or post-translational modifications (e.g., phosphorylated residues) which interact with an antibody. In some embodiments, an epitope may be a “conformational epitope,” which refers to an epitope involving a specific three-dimensional arrangement of the entity(ies) having or forming the epitope. For example, conformational epitopes of proteins may include combinations of amino acids and / or post-translational modifications from folded, non-linear stretches of amino acid chains.
[0149] Expression'. As used herein, “expression” of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5' cap formation, and / or 3' end processing); (3) translation of an RNA into a polypeptide or protein; and (4) post-translational modification of a polypeptide or protein.
[0150] Identity. As used herein, the term “identity” refers to the overall relatedness between polymeric molecules, e.g., between polynucleotide molecules (e.g. DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of the percent identity of two polynucleotide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H. and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).
[0151] Sample: As used herein, the term “sample” or “biological sample” refers to a subset of its tissues, cells or component parts (e.g. body fluids, including but not limited to blood, serum, plasma, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, and urine). Samples may further include a homogenate, lysate, or extract prepared from a whole organism or a subset of its tissues, cells or component parts, or a fraction or portion thereof, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, and organs. Samples may further refer to a medium, such as a nutrient broth or gel, which may contain cellular components or other biological materials, such as proteins (e.g., antibodies) or nucleic acid molecules.
[0152] Subject: As used herein, the term “subject” refers to any organism to which a composition in accordance with the disclosure may be administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g, mammals such as mice, rats, rabbits, non-human primates, and humans) and / or plants. A subject receiving, requiring, eligible for, or seeking medical treatment is referred to herein as a “patient.”
[0153] Target: As used herein, the term “target” refers to an entity of interest or attention, which may include a subject, an organ, a tissue, a cell, a protein, a nucleic acid, biomolecule, or a group, complex, or portion of any of the foregoing. In some embodiments, a target may be a protein or epitope thereof for which an antibody has affinity or for which an antibody is desired, designed, or developed to have affinity for. As used herein, the term “target” may also be used to refer to an activity of an agent that is directed to a particular object. For example, an antibody that has affinity for a specific protein “X” may be said to target protein X or may be referred to as an antibody targeting protein X or referred to as a protein X- targeting antibody. Similarly, an object that is the subject of an agent’s activity may be referred to as a “targeted” object. For example, where an antibody has affinity for a specific protein “X,” protein X may be referred to as being targeted by the antibody.
[0154] IV. Equivalents and scope
[0155] While various embodiments of the invention have been particularly shown and described in the present disclosure, it will be understood by those skilled in the art that various changes in form and details may be made without departing from the spirit and scope of the embodiments disclosed herein and set forth in the appended claims.
[0156] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather is as set forth in the appended claims.
[0157] In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of a group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or all group members are present in, employed in, or otherwise relevant to a given product or process.
[0158] It is also noted that the term “comprising” is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term “comprising” is used herein, the terms “consisting of’ and “or including” are thus also encompassed and disclosed.
[0159] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.
[0160] In addition, it is to be understood that any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to those of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiments of compositions disclosed herein can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.
[0161] All cited sources, for example, references, publications, databases, database entries, and art cited herein, are incorporated into this application by reference, even if not expressly stated in the citation. In case of conflicting statements of a cited source and the instant application, the statement in the instant application shall control.
[0162] Section and table headings are not intended to be limiting. EXAMPLES
[0163] Example 1. Siglecl2 is a novel target for acute myeloid leukemia
[0164] Siglecl2 was reported to be detected in solid epithelial tumors using immunohistochemistry (United States Publication Number US 2020 / 0003779). However, immunohistochemistry is a non-quantitative methodology and understanding relative siglecl2 expression levels between tumor and normal tissue is critical to understanding which cancers will be treatable using a siglecl2-targeted immunotherapeutic approach. mRNA levels of a specific target in tissue is an accepted measure of relative expression levels of a specific target. RNAseq data (mRNA levels quantified via next gen sequencing, NGS) from various public databases (TCGA project, Depmap Portal, CCLE, Blueprint Project, and GTEx) were analyzed to discover which cancers make the most suitable targets for siglecl2-targeted immunotherapy. Results presented in Fig. 1 show differential expression levels of siglecl2 between normal tissue and tumors originating in the same tissue (based in whole or in part on data generated by the TCGA Research Network). These results are summarized in Table 11 and reveal that certain solid tumors are preferable cancer targets for siglecl2-targeted immunotherapy than others, namely: cervical squamous cell carcinoma and endocervical adenocarcinoma; head and neck squamous cell carcinoma; kidney renal clear cell carcinoma; esophageal carcinoma and stomach and esophageal cancer.
[0165] Table 11. Increased siglecH mRNA expression in different solid tumors
[0166] Further database analysis [DepMap Portal, Broad (2020): DepMap 20Q2 Public, v4] revealed that when measuring mRNA levels (RNAseq) across 1304 different tumor cell lines, siglecl2 was most highly expressed in the leukemia cell lines, as shown in Fig. 2. In cancer cell lines of hematopoietic and lymphoid tissue origin, both AML (acute myeloid leukemia) and CML (chronic myeloid leukemia) cell lines had significantly greater siglecl2 mRNA expression than the other cell lines [based on 2020 Broad Institute CCLE (Cancer Cell Line Encyclopedia) mRNA expression (RNAseq) data, see Fig. 3], Between AML and CML, median siglecl2 mRNA expression in AML was 6-fold greater than median levels in CML.
[0167] CD33 is known to be highly expressed on AML cell lines and AML blasts in AML patients. The CD33-targeted Gemtuzumab Ozogamicin (GO, MYLOTARG®, Pfizer, New York, NY) is an antibody drug conjugate (ADC) that uses a calicheamicin warhead. GO is the only currently listed form of immunotherapy for AML. There are several other AML targets known to be expressed on AML cell lines and blasts in patients that are currently being investigated in clinical and preclinical studies as potential immunotherapeutic targets. Further RNAseq database analysis demonstrated that siglecl2 expression levels in AML cell lines compared quite favorably to mRNA levels of other AML targets [based on 2020 Broad Institute CCLE (Cancer Cell Line Encyclopedia) mRNA expression (RNAseq) data, see Fig. 4], CD33 expression levels on AML cell lines were comparable to those of siglecl2, supporting designation of siglecl2 as a possible target for immunotherapeutic development and treatment of AML.
[0168] While AML target over expression on AML blasts is important when evaluating potential immunotherapeutic targets, expression on normal tissues and hematopoietic cells can lead to toxicity and dose-limiting requirements. GO has on-target hematological toxicities associated with CD33 expression on hematopoietic progenitor cells that manifests as persistent thrombocytopenia and prolonged neutropenia (Castaigne, S. et al. Lancet. 2012, 379(9825): 1508-16). Fig. 5 shows mRNA expression levels of siglecl2 and other AML target proteins in common hematopoietic cells based on analysis of public mRNA expression data (Blueprint Consortium). Siglecl2 is mainly expressed, albeit at relatively low levels, in classical monocytes, macrophage and alternatively activated macrophage. Fig. 6 shows expression levels of siglecl2 and other AML target proteins in hematopoietic progenitor and stem cells based on analysis of public mRNA expression data (Blueprint Consortium). These cell types are rare, but critical with respect to common hematopoietic toxicities. A significant difference was observed between siglecl2 and other AML targets with siglecl2 having exceptionally low, or no detectable expression in these hematopoietic stem and progenitor cells. The combination of high over expression of siglecl2 on AML cells and lack of expression on hematopoietic stem and progenitor cells supports designation of siglecl2 as an exemplary target for AML immunotherapeutic development. Siglecl2 and CD33 mRNA expression was compared in normal tissues based on analysis of public data (The Genotype- Tissue Expression Project) and again demonstrated relatively low expression of siglecl2 in normal tissue (see Fig. 7), supporting an expected advantage of lower on-target toxi cities associated with systemic exposure to siglecl2-targeting immunotherapeutics. Overall, expression profile results from public RNAseq database analysis indicate that siglecl2 is an ideal target for antibody-based immunotherapeutic development and use for the treatment of siglecl2-expressing AML, CML, and solid tumors.
[0169] Antibodies specific for siglecl2 were generated by immunizing Trianni transgenic mice (United States Publication Number US2013 / 0219535). Endogenous immunoglobulin VH, DH and JH; VK and JK; and VX and JX gene segments have been replaced in these mice by the full repertoire of human counterpart gene segments. The human gene coding sequences are flanked by mouse cis-acting regulatory elements and recombination signal sequences allowing for a “normal” immune response, including isotype switching with heavy and light chain affinity maturation. The resulting human-mouse chimera antibodies contain human antibody variable domains flanked by mouse heavy and light chain immunoglobulin constant regions. These antibodies are more readily converted to fully human antibodies using standard methods to combine the human variable domains with human constant regions.
[0170] Trianni animals were immunized with an antigen prepared by fusion of soluble human siglecl2 extracellular (ecto) domain (S12ecto, UniProtKB Q96PQ1, amino acids 1-481, SEQ ID NO: 171) with a mouse Fc2a fragment (SEQ ID NO: 177), the resulting fusion protein referred to herein as “S12-Fc.” Mouse Fc was used in place of commonly used human Fc to minimize generation of antibodies against the Fc region. For S12-Fc preparation, DNA encoding full length human S12ecto was codon optimized, synthesized, and inserted into plasmid vectors for transient transfection and expression in mammalian cells. Expressed fusion protein was purified using protein A / G SEPHAROSE®.
[0171] After 6 weeks of immunization, serum samples from immunized mice were screened for the presence of siglecl2-specific immunoglobulins. Screening was carried out by enzyme- linked immunosorbent assay (ELISA) and by fluorescence-associated cell sorting (FACS). ELISA assays utilized assay plates coated with S12-Fc target antigen for immobilization of siglecl2-specific immunoglobulins from mouse serum samples, which were detected using anti-mouse light chain (kappa and lambda) secondary antibody conjugated to horseradish peroxidase (HRP). The level of bound secondary antibody was assessed by incubation with colorimetric peroxidase substrate followed by measurement of light absorbance intensity values obtained at 450 nm. For FACS analysis, serum samples were combined with U937 cells (Fc receptor blocked with 10% human serum), an AML cell line that overexpresses human siglecl2. Immunoglobulin binding to siglecl2 associated with these cells is a strong indicator of potential immunotherapeutic use to treat AML. Anti-mouse heavy chain fluorescent detection reagents were used to label cell surface-bound serum immunoglobulins before FACS analysis. Lymph node and spleen cells from the three best responders were harvested and fused with P3X63Ag8.653 mouse myeloma cells. After 10-14 days of selection, the resulting hybridoma library was single-cell cloned into 96-well culture plates using FACS. After 10-14 days of single cell expansion, all monoclonal hybridoma culture supernatants were screened for S12-Fc binding immunoglobulins by ELISA. Supernatant positive for S12-Fc-binding immunoglobulins was further screened by FACS for immunoglobulin binding to U937 cells. Results are shown in Table 12. The Table includes an antibody identification number (ID#) assigned to siglec!2-binding antibodies associated with each hybridoma culture. For ELISA results, background adjusted mean absorbance values obtained at 450 nm are shown. For FACS analysis, Flow Fluor MFI is the mean fluorescence intensity from flow cytometry assay (background MFI=100) and flow % gated is the percentage of cells having greater than background fluorescence.
[0172] Table 12. Antibody screening analysis
[0173] Many of the antibodies tested demonstrated strong association with U937 cell surfaces (flow % gated >10), including S0016, S0017, S0025, S0033, S0041, S0044, S0045, S0048, S0049, S0057, S0061, S0067, S0070, S0074, S0079, S0082, S0083, S0084, S0086, S0087, S0088, S0092, S0094, S0097, S0098, S0105, and S0106.
[0174] Antibodies were isolated from mouse ascites fluid or from hybridoma culture media by protein A capture and used for further analysis according to the following examples. domain
[0175] ELISA assays were conducted to assess siglecl2 domain specificity of antibodies identified during hybridoma screening described above. Antibodies binding to specific subdomains of S12ecto domain could provide certain advantages. For example, it is known that siglecl2 expresses two different membrane-bound isoforms: a long form (595 aa, UniProtKB Q96PQ1-1, SEQ ID NO: 172) containing four extracellular domains plus a transmembrane and cytosoplasmic domain; and a shorter isoform (477 aa, UniProtKB Q96PQ1-2, SEQ ID NO: 173) that contains only a single extracellular domain (Vset domain) plus the same transmembrane and cytoplasmic domain.
[0176] Antibodies that bind to the Vset2-C2setl region of siglec!2 (S12-V2C1) have the advantage of recognizing both long and short siglec!2 isoforms. From a therapeutic standpoint, where both long and short siglec!2 isoforms are expressed on a tumor cell, a S12- V2Cl-binding antibody will bind a greater number of siglec!2 molecules on the cell surface of a targeted cell, thus increasing the sensitivity and efficacy of the therapy.
[0177] Antibodies that specifically bind to the Vsetl region of siglec!2 (S12-V1) have the advantage of discriminating between the long and short siglec!2 isoforms. Such antibodies may be useful for targeting tumor cells expressing only the long isoform of siglec!2, while not targeting normal cells expressing the short form of siglec!2. S12-V1 antibodies may also be useful from a biomarker standpoint for discriminating between long and short siglec!2 isoforms.
[0178] Antibodies that specifically bind to the C2 region of siglec!2 (S12-C2) may be advantageous in targeting a region of the siglec!2 extracellular domain that is closer to the cell surface. Binding to cancer epitopes closer to the cell surface has been shown to provide greater sensitivity with respect to cell cytotoxicity in the context of a CD3 -mediated bispecific antibody (e.g., see Estey E.H. et al., Am J Hematol. 2018. 93:1267-91), thus S12- C2-specific antibodies may be candidates for S12-CD3 bispecific antibody development and immunotherapy.
[0179] Proteins corresponding with subdomains of S12ecto domain were prepared for use as ELISA target antigens. The subdomains prepared included S12-V1 (amino acids 1-142 of UniProtKB Q96PQ1, SEQ ID NO: 174), S12-V2C1 (native leader sequence with amino acids 143-358 of UniProtKB Q96PQ1, SEQ ID NO: 175), and S12-C2 (native leader sequence with amino acids 365-481 of UniProtKB Q96PQ1, SEQ ID NO: 176) domains. The two domains Vset2 and C2setl were combined since there is a naturally occurring inter-disulfide bond between the Vset2 and C2setl domains of siglec!2. To produce subdomain proteins, plasmids encoding each of S12-V1, S12-V2C1, and S12-C2 were prepared with additional nucleotides encoding a 6-His affinity tag (SEQ ID NO: 179), in addition to a StrepII affinity tag (aa sequence WSHPQFEK (SEQ ID NO: 180)) at subdomain C-termini for purification. Plasmids were transfected into human cell cultures for protein expression and subdomain proteins were isolated from culture media using Ni-IMAC (immobilized metal affinity chromatography) and STREP-TACTIN® SEPHAROSE® (GE Healthcare, Waukesha, WI) affinity chromatography purification.
[0180] For ELISA assays, purified subdomain proteins were passively immobilized on assay plates and incubated with media from hybridoma cultures described above before detection of bound anti -subdomain antibodies using anti-mouse (heavy / light) secondary antibody conjugated to horseradish peroxidase (HRP). Levels of bound secondary antibody were assessed by applying colorimetric substrate and measuring absorbance values at 450 nm. Mean absorbance values obtained for antibodies associated with each hybridoma culture are presented in Table 13. Absorbance values greater than 0.07 indicate specific binding.
[0181] Table 13. Antibody characterization analysis
[0182] Example 4. Antibody characterization by inter-siglec specificity
[0183] ELISA assays were also conducted to assess inter-siglec antibody specificity for other CD33-related siglecs. Siglecl2 is a member of the CD33-related siglec family. From the family, human siglec7 and siglec9 have the greatest sequence identity to human siglecl2. Specificity for siglecl2 over other CD33-related siglecs by candidate antibodies is a desirable property for reducing potential toxicity associated with off-target binding.
[0184] Fusion proteins of human siglec7 or siglec9 ectodomains fused with human Fc domains (R&D Systems, Minneapolis, MN) were immobilized on assay plates and incubated with media from hybridoma cultures described above before detection of bound antibodies using anti-mouse (heavy / light) secondary antibody conjugated to HRP. Levels of bound secondary antibody were assessed by applying colorimetric substrate and measuring absorbance values at 450 nm. Mean absorbance values obtained for antibodies associated with each hybridoma culture are presented in Table 14.
[0185] Of the antibodies with strong association with U937 cell surfaces (flow % gated > 10), most demonstrated lack of specificity for siglec7 and siglec9 (A450 >0.09), including S0016, S0017, S0025, S0033, S0041, S0044, S0045, S0048, S0049, S0057, S0061, S0067, S0070, S0074, S0079, S0082, S0083, S0086, S0087, S0088, S0092, S0094, S0097, S0105, and S0106.
[0186] Example 5. Siglecl2-dependent internalization
[0187] Internalization of siglecl2-bound anti-siglecl2 antibodies was assessed in U937 AML cells using anti-siglecl2 antibodies described in Example 2. U937 AML cells were cultured and duplicate wells were incubated with or without anti-siglecl2 antibodies (described in Example 2) or anti-CD33 antibody (P67.6, BioLegend, San Diego, CA) on ice for 1 hr. Cells were washed and resuspended in 800 pL ice cold complete media (10% FBS, RPMI) before plating 100 pL per well in 96-well plates. Cells were then incubated at 37°C and 5% CO2 to promote internalization. Internalization was halted at 15, 30, 45, 60, 90, and 120 minute time points by placement on ice before cells were harvested and washed with cold PBSB (PBS+0.1% BSA). Harvested cells were then incubated with phycoerythrin (PE)-conjugated goat anti-mouse antibody (1:400, Bethyl Laboratories, Montgomery, TX) for 30 min on ice. Cells were again washed with PBSB and analyzed by flow cytometry using a GUAVA® EASYCYTE™ Plus flow cytometer (MilliporeSigma, Burlington, MA) to assess percent surface expression and percent internalization of antibody-associated siglecl2 and CD33 at the time points evaluated. A comparison of average percent surface expression over time between siglecl2 (labeled using S0057 antibody) and CD33 is shown in Table 15. Table 15. Percent surface expression over time
[0188] The results demonstrate similar internalization levels over time between the two antibody-associated markers. A comparison of percent siglecl2 internalization observed at 2 hours with different anti-siglecl2 antibodies is presented in Table 16.
[0189] Table 16. Percent internalization
[0190] The results show internalization activity with each antibody tested, with highest activity among antibodies S0042, S0057, and SOI 14.
[0191] Example 6. Siglecl2 intracellular trafficking
[0192] Siglecl2-antibody complexes were assessed for intracellular trafficking to acidified cell compartments (e.g., the lysome) using acid sensitive dyes. Trafficking of internalized antibody-target complexes to acidified cellular compartments is desirable for some therapeutic antibody applications, including some utilizing antibody-drug conjugates (ADCs). Such trafficking may facilitate ADC drug release and / or activation. ZENON® labeling reagent (Thermo Fisher Scientific, Waltham, MA) includes an anti-mouse Fab fragment labeled with a pH sensitive dye that increases green fluorescence upon acidification. S0057 anti-siglecl2 antibody was pre-incubated with 750 nM ZENON® labeling reagent for 15 min in PBSB. 50 nM P67.6 (anti-CD33) was similarly prepared and used for comparison (as internalized CD33-antibody complexes are known to traffic to lysosomes). Resulting complexes were added to separate wells containing U937 cells and incubated for 0, 4, or 24 hours at 37°C at 5% CO2. Green fluorescence was measured at each time point using a GUAVA® EASYCYTE™ Plus flow cytometer. Resulting mean fluorescence intensity (MFI) values are presented in Table 17.
[0193] Table 17. Acidification analysis results
[0194] Acidification was comparable between siglec!2-bound and CD33-bound complexes validating the potential of siglec!2-specific antibody targeting as an option for ADC therapeutics.
[0195] Example 7. ADC cytotoxicity on AML cells
[0196] Anti-siglecl2 antibodies were assessed for utility in delivering cytotoxic payloads to cells. 1 mg S0057 was used to prepare a 3 mg / mL antibody solution in PBS (pH 7.8) / 30% propylene glycol and combined with 40 nmols of N-succinimidyl ester activated MYLOTARG® linker / payload (Levena Biopharma, San Diego, CA). MYLOTARG® has an acid-sensitive linker with a calicheamicin payload. The antibody solution was incubated overnight at room temperature under gentle shaking. Resulting S0057-ADC was purified from unconjugated linker / payload by buffer exchange and size-exclusion chromatography. U937 AML cells were plated in a 96-well plate and incubated in complete media (10% FBS, RPMI + 100 pg / mL human IgG) with S0057-ADC titrated from 100 to 0.1 nM. Cells were incubated for 3 days at 37°C and 5% CO2, after which average percent cell viability was determined using GUAVA® VIACOUNT® reagent (Luminex, Austin, TX) and GUAVA® EASYCYTE™ Plus flow cytometer. Average percent viability values with each antibody concentration tested are presented in Table 18.
[0197] Table 18. Average percent cell viability
[0198] S0057-ADC concentrations as low as 6.25 nM were capable of reducing cell viability by nearly half.
[0199] Example 8. Siglecl2 detection in AML bone marrow
[0200] Bone marrow aspirate from patients with AML or acute promyelocytic leukemia (APL, negative control) was fixed with 10% formalin and used to prepare and mount 5- micron thick sections. Antigen retrieval was performed by incubating sections in antigen retrieval buffer (pH 9) for 40 minutes. Sections were treated with blocking buffer with 10% normal horse serum and incubated with S0102 anti-Siglecl2 antibody (1:150). Bound antibodies were detected using peroxidase-conjugated secondary antibodies and development with 3,3'-diaminobenzidine (DAB) chromogen. Sections were counterstained with hematoxylin and eosin and visualized microscopically. Siglecl2 staining of AML blasts was observed in AML patient bone marrow, while staining was absent in APL patient tissues.
[0201] Example 9. Siglecl2 specificity evaluation
[0202] To verify anti-siglecl2 antibody specificity for native siglecl2 (over other siglec family members), cross-reactivity analysis was carried out using flow cytometry. Expi 293 cells were grown in 6 well plates and transfected with 2.5 mg of pcDNA3.1 expression vectors (Thermo Fisher Scientific, Waltham, MA) with inserts encoding siglec6, siglec7, siglec8, siglec9, or siglecl2 proteins with C-terminal FLAG tags. The following day, Expi293 enhancers were added. On day 2 (post-transfection) cells were washed in PBSB and aliquoted into plastic V-bottomed plates at a density of 5 x 105cells / well. An aliquot was also used for Western blot analysis to confirm siglec expression (using anti-FLAG antibody as described below). Plated cells were incubated with anti-siglecl2 antibodies at a concentration of 500 nM or siglec-specific control antibody (all from R&D Systems, Minneapolis, MN; Siglec6-specific clone 767329; Siglec8-specific clone 837535; Siglec9-specific clone 191240) at a concentration of 12.5 pg / mL for 2 hours on ice. Cells were then washed with ice cold PBSB and incubated with PE-goat anti mouse H / L chain secondary antibody (1:400 in PBSB) for 30 minutes on ice. Cells were again washed with ice cold PBSB and analyzed for surface staining based on fluorescence intensity determined by GUAVA® EASYCYTE™ Plus flow cytometer. Resulting MFI values are presented in Table 19.
[0203] Table 19. Surface staining results
[0204] All anit-siglecl2 antibodies tested bound to siglecl2-expressing cells and demonstrated little to no binding of other siglec proteins.
[0205] For FLAG-specific Western blot analysis, cells were lysed in radioimmunoprecipitation assay (RIP A) buffer and run on 4-12% NUPAGE™ gel (Thermo Fisher Scientific, Waltham, MA). Proteins were transferred onto PVDF membranes and blocked with 3% BSA in PBS. Anti-FLAG primary antibody (anti-FLAG OTI4C5, Origene Biotechnology, Rockville, MD) was diluted 1:2000 in PBS with 0.05% TWEEN® 20 and 0.3% BSA and used to treat PVDF membranes overnight at 4°C. Membranes were washed and incubated with alkaline phosphatase (AP)-labeled goat anti mouse H / L chain secondary antibody for 30 minutes at room temperature. Membranes were washed again and developed with CDP-STAR® chemiluminescent detection reagent for digital imaging of labeled bands. Results confirmed expression of siglec proteins.
[0206] Example 10. S0057 epitope evaluation
[0207] An antibody binding competition assay was carried out to confirm S0057 epitope and assess epitope overlap with other anti-siglec!2 antibodies. A fusion protein of S12 V2C1 (SEQ ID NO: 175) and mouse Fc region fragment m2cFc (SEQ ID NO: 178) was prepared and used to coat 96-well plates in PBS overnight at 4°C. Plates were then blocked with 3% BSA / PBS for one hour before addition of biotinylated S0057 (15 nM) and a titration of unlabeled antibody (200 nM to 6.2 nM of S0057, S0023, S0102, or S0042). Plates were incubated for two hours and washed before incubation with streptavidin- Alkaline phosphatase conjugate (1:5000 in PBS / TWEEN® 20 with 0.3% BSA) for 30 min. Plates were again washed and incubated with CDP-STAR® chemiluminescence substrate before chemiluminescence analysis using a BioTek CYTATION™ 5 instrument (Winooski, VT).
[0208] Mean luminescence values obtained are presented in Table 20.
[0209] Table 20. Mean luminescence values
[0210] V2Cl-specific antibodies S0023 and S0102 (see Example 3) did not effectively compete with S0057, thus indicating that the S0057 epitope most likely does non-overlap with S0023 or S0102 epitopes. The unlabeled S0057 demonstrated effective competition as a positive control and S0042 (VI -binding negative control) did not compete for binding.
[0211] Example 11. S0057 binding affinity
[0212] Siglecl2 binding kinetics were assessed for S0057 whole antibody and corresponding Fab fragment (obtained by whole antibody digestion). A fusion protein of S12 V2C1 (SEQ ID NO: 175) and mouse Fc region fragment m2cFc (SEQ ID NO: 178) was prepared and used to coat 96-well plates in PBS overnight at 4°C. Plates were then blocked with 3% BSA / PBS for one hour before addition of S0057 Fab fragment or S0057 whole antibody at titrations from 3 pM to 50 pM (in 0.3% BSA / PBS) using 3-fold dilutions. Plates were then incubated for 2.5 hours at room temperature under gentle shaking. Plates were washed and incubated with secondary antibody [1: 10,000 goat anti-mouse Kappa chain HRP conjugate (Bethyl Laboratories, Montgomery, TX) in 0.3% BSA / PBS / Triton X-100] for 30 min at room temperature. Plates were again washed before addition of colorimetric peroxidase substrate, quenching, and absorbance measurement at 450 nm. Absorbance values were used to determine equilibrium dissociation constant (Kd) values for Fab and whole antibody formats. S0057 Fab fragment Kd was determined to be 4.8 nM and whole antibody Kd to be 2.8 nM. In subsequent Examples 12 to 18, the complete antibody S0057 is referred to as MABL57. Example 12. Preparation of a single chain Fv (scFv57) ribosome display construct
[0213] A polynucleotide DNA sequence (SEQ ID NO: 181) for ribosome display was synthesized containing a single chain variable fragment (scFv57) coding for the human variable region of MABL57. The scFv57 sequence consists of nucleotide sequence (SEQ ID NO: 182) coding for the heavy chain variable region of MABL57 and the light chain variable region of MABL57 (SEQ ID NO: 183), separated by a sequence coding for a 20-amino acid spacer. Upstream of the scFv is a T7 promoter sequence, a 5’ stem loop, a Shine Dalgamo ribosomal binding site and a START codon. Downstream of the scFv57 sequence is a M13 gene 3 spacer sequence, a SecM ribosome tunnel interacting sequence and a 3’ stem loop. No STOP codon is present in-frame of the scFv57 coding sequence to allow for ribosome stalling and increased stability of the scFv / ribosome / mRNA complex.
[0214] Example 13. Preparation of a Single Chain Fab (ScFab57) ribosome display construct
[0215] A polynucleotide DNA sequence (SEQ ID NO: 184) for ribosome display was synthesized containing a single chain antibody fragment (scFab57) coding for the MABL57 human variable region in context of the human heavy chain IgGl constant region’s first domain (SEQ ID NO: 266) and human kappa light chain constant region (SEQ ID NO: 267). The heavy and light chain Fab fragments were separated by a 100 amino acid glycine / serine- rich spacer to form the single chain Fab construct. Upstream of the MABL57 kappa light chain sequence is a T7 promoter sequence, a Shine Dalgamo ribosomal binding site and a START codon. Downstream of the MABL57 heavy chain IgGl first domain constant region there are two SecM ribosome tunnel interacting sequences.
[0216] Example 14. scFab Scanning Mutagenesis Library
[0217] Saturation mutagenesis, also known as site saturation, is a random mutagenesis technique used in protein engineering, in which a single codon or set of codons is substituted with all possible amino acids at the position. Saturation scanning mutagenesis involves performing a site saturation at every site in the protein, resulting in a library of size [20 x (number of residues in the protein)] that contains every possible point mutant of the protein). In the present example, saturation scanning mutagenesis was performed by introducing all 20 amino acid codons into a single amino acid position at every CDR residue (Kabat numbering) in both heavy and light chains of MABL57 using primers containing NNK degeneracy with 15 wild type nucleotides hybridizing upstream and 12 nucleotides downstream of the target codon in the MABL57 Fab template (SEQ ID NO: 184). A total of 57 downstream constructs containing single codon mutations were generated using the 57 forward mutant primers (SEQ ID NOs: 185-241) and a universal reverse primer pRDFabrev (SEQ ID NO: 242).
[0218] Single codon mutant downstream fragments were prepared by PCR in the following manner: 25 pL Q5 Polymerase 2x PCR mix (New England Biolabs); 2.5 pL of 10 pM mutant fwd primer (SEQ 185-241); 2.5 pL of 10 pM pRDFabrev primer; 1 pL of 10 ng / pL template (SEQ 184); 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melting for 30 sec, annealing for 15 seconds at 62-70° C (depending on mutant primer sequence) and extending at 72° C for 1 minute with a final 2- minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to manufacturer’s (Promega) protocol.
[0219] The MABL57 Fab library constructs were made using Overlap-Extension PCR (OE- PCR) using the gel-purified mutant PCR product and a universal upstream fragment (SEQ ID NO: 243) generated by PCR using primers pRD57for (SEQ ID NO: 244) and pRD57uprev (SEQ ID NO: 245) with MABL57 Fab template (SEQ ID NO: 184).
[0220] The universal upstream fragment was prepared by PCR in the following manner: 25 pL Q5 Polymerase 2x PCR mix (New England Biolabs); 2.5 pL of 10 pM pRD57for (SEQ ID NO: 244); 2.5 pL of 10 pM pRD57uprev (SEQ ID NO: 245); 1 pL 10 ng / pL template (SEQ ID NO: 184); 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 70° C and extend at 72° C for 1 minute with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0221] The universal upstream fragment was joined with the downstream mutant fragment by Overlap Extension PCR in the following manner: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 1 pL single codon CDR mutant (~50 ng); 1 pL universal upstream fragment (~85 ng); 18 pL water. The following PCR program was used: 1 cycle 95° C melt for 30 sec.; 10 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 63° C and extend at 72° C for 30 seconds. The reaction tube was removed and primers were added as follows: 2.5 pL 10 pM pRD57for and 2.5 pL 10 pM pRD57rev. The following PCR conditions were used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 70° C and extend at 72° C for 1 minute with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0222] The MABL57 Fab scanning mutagenesis library was arranged into a heavy chain library (Fab57HC) and a light chain library (Fab57LC). The heavy chain library was composed of equimolar concentrations of codon mutants targeting the 31 heavy chain CDR residues (SEQ ID NO: 246, SEQ ID NO: 247 and SEQ ID NO: 248). The light chain library was composed of equimolar concentrations of codon mutants targeting the 26 light chain CDR residues (SEQ ID NO: 249, SEQ ID NO: 250 and SEQ ID NO: 251).
[0223] The MABL57 Fab scanning mutagenesis library was converted into the scFv57 scanning mutagenesis ribosome display library using OE-PCR. Generation of the heavy chain mutant scFv57 library (scFv57HC) was carried out by PCR amplification of Fab57HC library using FabtoFvHCfor (SEQ ID NO: 252) and FabtoFvHCrev (SEQ ID NO: 253) primers using the MABL57 Fab heavy chain library as template.
[0224] The heavy chain mutants for the scFv library (57FvHCmut) conversion or 57FvHC wild type for scFvLC library were prepared as follows: 25 pL Q5 Polymerase 2x PCR mix (New England Biolabs); 2.5 pL of 10 pM FabtoFvHCfor (SEQ ID NO: 252); 2.5 pL of 10 pM FabtoFvHCrev (SEQ ID NO: 253); 1 pL of 12 ng / pL Fab57HC library for 57FvHCmut or 1 pL (~10 ng) Fab57 template (SEQ ID NO: 184); 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melting for 30 sec, annealing for 15 seconds at 70° C and extending at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0225] This FvHC library PCR product was used with the 5Tongfor primer (SEQ ID NO: 254) to generate an upstream scFv57HC library fragment for scsFv57 libraries by OE-PCR as follows: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2 pL 57FvHCmut (100 ng); 1 pL of 1 pM 5Tongfor (SEQ ID NO: 254); 17 pL water. Alternatively, for the scFv57LC library (wild type 57FvHC sequence): 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2 pL 57FvHCWT (100 ng); 1 pL of 1 pM 5’longfor (SEQ ID NO: 254); 17 pL water. The following PCR program was used: 1 cycle 95° C melt for 30 sec.; 10 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 63° C and extend at 72° C for 30 seconds. The reaction tube was removed and primers were added: 2.5 pL 10 pM 5’T7for (SEQ ID NO: 259) and 2.5 pL 10 pM FabtoFvrev (SEQ ID NO: 256). The following PCR was performed: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 67° C and extend at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0226] The scFv57HC library downstream fragment containing constant MABL57 light chain sequence was generated by OE-PCR using a fragment made by PCR using primers FabtoFvLCfor (SEQ ID NO: 255) and FabtoFvLCrev (SEQ ID NO: 256) using SEQ ID NO: 184 as template and the 3’ constant region fragment (SEQ ID NO: 260) made by PCR using primers new3’fragfor (SEQ ID NO: 257) and 3’fragrev (SEQ ID NO: 258) using SEQ ID NO: 181 as template.
[0227] The 57LC mutants were prepared for scFv library (57FvLCmut) conversion or for 57FvLC wild type for scFvHC library conversion as follows: 25 pL Q5 Polymerase 2x PCR mix (New England Biolabs); 2.5 pL of 10 pM FabtoFvLCfor (SEQ ID NO: 255); 2.5 pL of 10 pM FabtoFvLCrev (SEQ ID NO: 256); 1 pL of 12 ng / pL Fab57LC library for 57FvLCmut or 1 pL (~10 ng) Fab57 template (SEQ ID NO: 184); 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melting for 30 sec, annealing for 15 seconds at 67° C and extend at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0228] The 3’ constant region fragment (SEQ ID NO: 260) was prepared as follows: 25 pL Q5 Polymerase 2x PCR mix (New England Biolabs); 2.5 pL of 10 pM new3’fragfor (SEQ ID NO: 257); 2.5 pL of 10 pM 3’fragrev (SEQ ID NO: 258); 1 pL of scFv57 template (SEQ ID NO: 181); 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melting for 30 sec, annealing for 15 seconds at 65° C and extend at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0229] Preparation of the downstream scFv fragment containing 57LC and 3’ constant region using OE-PCR was performed as follows: for the scFv57LC library: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2 pL (100 ng) 57FvLCmut; 2 pL (100 ng) 3’ constant region fragment; 16 pL water. Alternatively, for the scFv57HC library: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2 pL (100 ng) 57FvLCWT; 2 pL (100 ng) 3’ constant region fragment; 16 pL water. The following PCR conditions were used: 1 cycle 95° C melt for 30 sec.; 10 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 63° C and extend at 72° C for 30 seconds. The reaction tube was removed and primers added: 2.5 pL 10 pM FabtoFvfor (SEQ ID NO: 255) and 2.5 pL 10 pM 3’fragrev (SEQ ID NO: 258). The following PCR conditions were used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 67° C and extend at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0230] The scFv57LC library and scFv57HC library were constructed in the same way by OE-PCR joining of upstream and downstream Fv fragments constructed above. For the scFv57HC library the upstream 57HCmut fragment was joined with the downstream wild type 57FvLC fragment; for the scFv57LC library the wild type 57FvHC fragment was joined with the downstream 57FvLCmut fragments.
[0231] Construction of scFv57HC and scFv57LC libraries by OE-PCR was performed as follows. For the scFv57HC library: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2 pL (100 ng) 57FvHCmut upstream fragment; 2 pL (100 ng) 57FvLCWT downstream fragment; 16 pL water. For the scFv57LC library: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2 pL (100 ng) 57FvLCmut downstream fragment; 2 pL (100 ng) 57FvHCWT upstream fragment; 16 pL water. The following PCR conditions were used: 1 cycle 95° C melt for 30 sec.; 10 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 63° C and extend at 72° C for 30 seconds. The reaction tube was removed and primers added: 2.5 pL 10 pM 5’T7for (SEQ ID NO: 259) and 2.5 pL 10 pM 3’fragrev (SEQ ID NO: 258). The following PCR conditions were used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 67° C and extend at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0232] Both scFv and scFab scanning mutagenesis constructs were subjected to multiple rounds of ribosome display enrichment. sc57HC mutant and sc57LC mutant library sequences for both Fv and Fab constructs were independently enriched over three rounds of ribosome display. The following description is for scFv57 ribosome display, but the same method was used for the ribosome display enrichment of scFab57 constructs. The initial scFv57 libraries were transcribed into mRNA, which was used for the first round of ribosome display. In vitro translation of the initial library mRNA formed scFv protein / ribosome / mRNA complexes which were selected for binding to siglecl2-V2Cl (SEQ ID NO: 261) domain (with disulfide-biotin modification) and isolated from unbound scFv / ribosome / mRNA complexes using streptavidin-magnetic beads. After extensive washing of beads, bound complexes were eluted using reducing agent dithiothreitol (DTT). Eluted mRNA was recovered and used for first-strand cDNA synthesis and followed by PCR. The RT-PCR product was gel purified and used for transcription of mRNA for a subsequent round of Ribosome Display or the RT-PCR product could be cloned or sequenced for identification of enriched scFv sequences.
[0233] Preparation of biotinylated-Siglecl2-V2Cl was performed as follows. An aliquot of 90 pg (100 pL of 0.9 mg / mL) of purified Siglecl2-V2Cl in phosphate buffered saline (PBS) was labeled with 30x molar excess (16 pg) of sulfo-NHS-SS-biotin (ThermoFisher Scientific) for 2 hrs at room temperature. Siglecl2-SS-biotin was purified using an Illustra G50 micro desalting column (Cytiva) yielding 100 pL of 0.65 mg / mL product.
[0234] The following is a detailed description of a single round of ribosome display:
[0235] Both scFv and scFab scanning mutagenesis constructs were subjected to multiple rounds of ribosome display enrichment. sc57HC mutant and sc57LC mutant library sequences for both Fv and Fab constructs were independently enriched over three rounds of ribosome display. The following description is for scFv57 ribosome display, but the same method was used for the ribosome display enrichment of scFab57 constructs. The initial scFv57 libraries were transcribed into mRNA, which was used for the first round of Ribosome Display. In vitro translation of the initial library mRNA formed scFv protein / ribosome / mRNA complexes which were selected for binding to siglecl2-V2Cl (SEQ ID NO: 261) domain (with disulfide-biotin modification) and isolated from unbound scFv / ribosome / mRNA complexes using streptavidin-magnetic beads. After extensive washing of beads, bound complexes were eluted using reducing agent dithiothreitol (DTT). Eluted mRNA was recovered and used for first-strand cDNA synthesis and followed by PCR. The RT-PCR product was gel purified and used for transcription of mRNA for a subsequent round of Ribosome Display or the RT-PCR product could be cloned or sequenced for identification of enriched scFv sequences.
[0236] Preparation of biotinylated-Siglecl2-V2Cl was performed as follows, an aliquot of 90 pg (100 pL of 0.9 mg / mL) of purified Siglecl2-V2Cl in phosphate buffered saline (PBS) was labeled with 30x molar excess (16 pg) of sulfo-NHS-SS-biotin (ThermoFisher Scientific) for 2 hrs at room temperature. Siglecl2-SS-biotin was purified using an Illustra G50 micro desalting column (Cytiva) yielding 100 pL of 0.65 mg / mL product.
[0237] The following is a detailed description of a single round of ribosome display. Transcription of scFv57 DNA was carried out using the HiScribe T7 kit (New England Biolabs). An aliquot of 8 pL DNA (-100 ng - 1000 ng) was mixed with 10 pL 2x buffer and 2 pL of enzyme mix. Transcription was carried out at 37° C for 2 hours. The transcribed mRNA was purified using an RNA clean up column (New England Biolabs) according to the manufacturer’s protocol. The scFv57 / ribosome / mRNA complexes were formed using PURE Express in vitro translation kit (without release factors; New England Biosystems): 10 pL solution A, 7.5 pL solution B (60 pmol ribosomes), 1 pL disulfide solution 1 (NEB), 1 pL disulfide solution 2 (NEB), 1 pL murine RNase inhibitor (New England Biosystems), 6 pmol of mRNA and water to 25 pL total volume. Translation was carried out at 37° C for 30 minutes and then immediately put on ice. The translation reaction was diluted with 225 pL of WBTH buffer (50 mM Tris pH 7.5, 50 mM magnesium acetate, 150 mM NaCl, 0.1% Tween20, 4% BSA, 1% milk protein, 100 pg / mL yeast RNA, 2 mg / mL heparin sodium). M280 streptavidin coated magnetic beads (Dynal, Invitrogen) were blocked with WBTH buffer for 30-60 min. The diluted translation reaction was pre-cleared with 100 pL M280 beads by incubating for 10-20 min at 4° C, followed by bead removal using a magnet. The pre-cleared translation reaction was incubated with Siglecl2 V2C1-SS -biotin (50 nM for first round, 5 nM for second and third round of ribosome display) for 1 hr rotating at 4° C. scFv57 / ribosome / mRNA bound to Siglecl2 V2Cl-SS-biotin was selected by incubating with 50 pL M280 beads for 10 minutes on ice. The magnetic beads were isolated using a magnet and washed with 1 mL of ice-cold wash buffer (50 mM Tris pH 7.5, 50 mM magnesium acetate, 150 mM NaCl, 0.1% Tween20). Magnetic beads were isolated using a magnet. The wash step was repeated for a total of 5 washes. The magnetic bead-bound scFv57 / ribosome / mRNA complexes were eluted by incubating with 45 pL of elution solution (wash buffer + 50 mM DTT, 10 pg / mL yeast RNA, RNase inhibitor) for 2 hrs rotating at room temperature. The elution was recovered from magnetic beads using a magnet and supplemented with 5 pL of 0.5 M EDTA (pH 8) and incubated at room temperature for 30 minutes to ensure RNA is dissociated from the ribosome complex. The eluted mRNA (plus yeast carrier RNA) was precipitated by addition of 5 pL of 3 M sodium acetate and 130 pL pure ethanol and incubated overnight at -20° C. The ethanol precipitate was centrifuged at 20,000 g for 10 min at 4° C. The recovered pellet was washed with 0.5 mL ice-cold 70% ethanol and recovered by centrifugation. The RNA pellet was allowed to air dry for 5-10 minutes and then dissolved in 6 pL of nuclease-free water. In preparation for first-strand cDNA synthesis, 2 pL of 10 pM 3’fragrev primer (SEQ ID NO: 258) was pre-annealed with the 6 pL RNA-pellet solution by incubating at 65°C for 5 min and immediately put on ice. Using the Protocript II first-strand kit (NEB) and the 8 pL pre-annealed RNA solution, a 20 pL first-strand reaction was carried out at 42° C for 1 hr, followed by a 5 -minute 80° C heat kill. A 5 pL aliquot of the first-strand reaction was immediately amplified by PCR using: 25 pL 2x Q5 polymerase (NEB), 2.5 pL 10 pM 5’T7for (SEQ ID NO: 259), 2.5 pL 10 pM 3’fragrev (SEQ ID NO: 258), 15 pL water using the following PCR program: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melt for 30 sec, anneal for 15 seconds at 67° C and extend at 72° C for 1 minute with a final 2-minute extension at 72° C. The RT-PCR product could be used for a subsequent round of ribosome display or analyzed by sequence analysis.
[0238] Example 17. Next Generation Sequencing
[0239] Paired-end sequencing (2x250bp) was performed by Azenta Life Sciences on an Illumina Miseq platform. A 268-nucleotide amplicon covering all three CDRs within the HCFv region was amplified from the scFv57HC library using specific forward (SEQ ID NO: 262) and reverse primers (SEQ ID NO: 263) containing partial adapter sequences. A 249- amplicon covering all three CDRs within the LCFv region was amplified from the scFv57LC library using specific forward (SEQ ID NO: 264) and reverse (SEQ ID NO: 265) primers containing partial adapter sequences. After amplicon gel purification, the concentration of dsDNA was normalized to 20 ng / pL using the Quant-it fluorescence assay (Invitrogen). Amplicon preparation for Next Gen Sequencing was performed as follows. For scFv57HC: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2.5 pL 10 pM NGSHCfwd (SEQ ID NO: 262); 2.5 pL 10 pM NGSHCrev (SEQ ID NO: 263); 1 pL 3rdround scFv57HC RT-PCR product or 1 pL scFv57HC initial library; 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melting for 30 sec, annealing for 15 seconds at 67° C and extending at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0240] For scFv57LC: 25 pL Q5 Polymerase 2x mix (New England Biolabs); 2.5 pL 10 pM NGSLCfwd (SEQ ID NO: 264); 2.5 pL 10 pM NGSLCrev (SEQ ID NO: 265); 1 pL 3rdround scFv57LC RT-PCR product or 1 pL scFv57LC initial library; 19 pL water. The following PCR program was used: 1 cycle 95° C melting for 30 sec.; 30 cycles of 95° C melting for 30 sec, annealing for 15 seconds at 64° C and extending at 72° C for 30 seconds with a final 2-minute extension at 72° C. The PCR products were separated on a 1% agarose gel and the desired product was removed with a razor blade and purified using SV Wizard PCR gel purification columns according to the manufacturer’s (Promega) protocol.
[0241] Example 18. Analysis of scFv57 and scFab57 CDR Scanning Mutagenesis
[0242] The objective was to measure whether specific amino acids were enriched or diminished with respect to the wild-type amino acids at every MABL57 CDR residue over the course of three rounds of ribosomal display selection against MABL57. Dramatic changes in amino acid representation at specific CDR residues reveal changes in CDR sequence that alone or in combination can result in beneficial properties such as increased affinity or stability.
[0243] NGS sequencing results were filtered to eliminate nucleotide sequences containing any indels and nucleotide substitutions greater than four. These sequences were converted into a FASTA format and along with associated number of reads per sequence and were uploaded into the sequence alignment and data analysis program XLibrary Display 2.48. Sequences were translated in the proper frame and aligned using “simple global alignment”. Aligned amino acid sequences were sorted according to mutation and sequence. Wild type nucleotide sequence and sequences containing STOP codons were not included in the analysis. Only single amino acid substitutions within the 6 CDRs (Kabat numbering) of MABL57 were included in the analysis.
[0244] The number reads for every nucleotide sequence resulting in a specific amino acid substitution at every CDR residue was summed and tabulated for the initial scFv57 and 3rdround scFv57 libraries. Each summed value was divided by the total number of reads for the library being analyzed to arrive at a frequency of substitution of a specific amino acid at a specific CDR residue. When no reads were recorded for an amino acid change, the frequency was calculated to be the reciprocal of total number of reads for the library. The baseline frequency for wild type amino acids at each CDR residue was calculated to be the number of reads resulting in silent mutations (non-wild type nucleotide sequence resulting in wild type amino acid sequence) divided by total number of reads in that library. Frequency values for each amino acid substitution for every CDR residue in both initial and 3rdround libraries are reported in Tables 21-26 for scFv constructs and 31-36 for scFab constructs. The enrichment or depletion of an amino acid at a specific CDR residue through the ribosome display selection process was expressed as an enrichment factor, calculated to be the ratio of the frequency in the 3rdround library and the frequency in the initial library. Enrichment factors for all amino acids at all CDR residues are reported in Tables 27-28 and 37-38. Enrichment factors for all amino acids at a specific CDR residue are summed to provide a total enrichment factor for that CDR residue. Total enrichment factors can be used to identify hot spots or cold spots within the CDR. Hot and cold spots can also be defined as a CDR residue position that accepts amino acid changes that can result in increased affinity and cold spots are CDR residues that when mutated tend to lead to decreased binding to target of interest. Table 30 shows the total enrichment factor for all CDR residues (Kabat numbering) in MABL57 heavy chain and light chain. For scFv constructs, an enrichment factor 3-times greater than the wild type / native MABL57 CDR residue was used to determine preferred amino acids at any specific CDR residue; for scFab constructs, an enrichment factor of 1-time or greater than the wild type / native MABL57 CDR residue was used to determine preferred amino acids at any specific CDR residue. Tables 29 and 39 show potential amino acid changes for all CDR residues in both MABL57 heavy chain and light chain, including MABL57 wild type CDR residues. CDR residue positions of either high or low tolerance for amino acid substitutions was determined by total sum of enrichment factors for every amino acid at every CDR residue. Low total enrichment factors indicate a position of low tolerance for amino acid substitution (“cold spot”) and high total enrichment factors indicate a position of high tolerance for amino acid substitution (“hot spot”). Total enrichment factors for all CDR residues are summarized in Tables 30 and 40 for scFv57 and scFab57, respectively.
[0245] Variants of scFv57 and scFab57 including at least some of the preferred substitutions of Tables 29 and 39, respectively, may have enhanced affinity for siglecl2 relative to MABL57, particularly if they occur at the hot spots indicated by the enrichment factors summarized in Tables 30 and 40. Such variants are soundly and reasonably predicted to be useful as therapeutic agents for neutralizing Siglecl2 in treatment of various diseases and disorders such as the diseases and disorders described hereinabove. Table 21A. MABL57 heavy chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC initial library
[0246] Table 21B. MABL57 heavy chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC library after 3 rounds of ribosome display selection
[0247] Table 22A, Part 1. MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC initial library - showing the first 7 amino acids of WISAYNGFTRSTOKFOG (SEQ ID NO 349) Table 22A, Part 2. MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC initial library - showing the last 9 amino acids of WISAYNGFTRSTQKFQG (SEQ ID NO 349) Table 22B, Part 1. - MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC library after 3 rounds of ribosome display selection of WISAYNGFTRSTQKFQG (SEQ ID NO. 349)
[0248] Table 22B, Part 2. - MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC library after 3 rounds of ribosome display selection of WISA YNGFTRSTQKFQG (SEQ ID NO. 349) Table 23A. MABL57 heavy chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC initial library
[0249] Table 23B. MABL57 heavy chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57HC library after 3 rounds of Ribosome Display selection.
[0250] Table 24A, Part 1. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC initial library - showing RASOSVSSFLA (SEQ ID NO. 329)
[0251] Table 24A, Part 2. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC initial library - showing RASOSVSSFLA (SEO ID NO. 329)
[0252] Table 24B, Part 1. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC after 3 rounds of Ribosome Display selection - showing RASOSVSSFLA (SEQ ID NO. 329) Table 24B, Part 2. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC after 3 rounds of Ribosome Display selection - showing RASOSVSSFLA (SEO ID NO. 329)
[0253] Table 25A. MABL57 light chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC initial library
[0254] Table 25B. MABL57 light chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC after 3 rounds of ribosome display selection
[0255] Table 26A. MABL57 light chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC initial library
[0256] Table 26B. MABL57 light chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFv57LC library after 3 rounds of ribosome display selection
[0257] Table 27A. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 heavy chain CDR1.
[0258] Table 27B, Part 1. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 heavy chain CDR2 - showing WISAYNGFTRSTOKFOG (SEQ ID NO. 349) Table 27B, Part 2. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 heavy chain CDR2 - showing WISAYNGFTRSTQKFQG (SEO ID NO. 349)
[0259] Table 27C. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 heavy chain CDR3.
[0260] Table 28A, Part 1. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 light chain CDR1 - showing RASOSVSSFLA
[0261] (SEQ ID NO. 329)
[0262] Table 28A, Part 2. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 light chain CDR1 - showing RASOSVSSFLA
[0263] (SEQ ID NO. 329)
[0264] Table 28B. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 light chain CDR2 Table 28C. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFv constructs - MABL57 light chain CDR3 Table 29A, Part 1. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFv constructs in the heavy chain - showing residues 1-8 of 17 Table 29A, Part 2. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFv constructs in the heavy chain - showing residues 9-17 of 17 Table 29B, Part 1. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFv constructs in the light chain - showing residues 1-5 of 11
[0265] Table 29B, Part 2. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFv constructs in the light chain - showing residues 6-11 of 11
[0266] Table 30A. Total enrichment factors (sum of all amino acid enrichment factors) for all CDR residues in MABL57 scFv constructs in the heavy chain. The CDR region is defined by Kabat numbering Table 30B. Total enrichment factors (sum of all amino acid enrichment factors) for all
[0267] CDR residues in MABL57 scFv constructs in the light chain. The CDR region is defined by Rabat numbering
[0268] Table 31A. MABL57 heavy chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC initial library Table 31B. MABL57 heavy chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC after 3 rounds of Ribosome Display selection
[0269] Table 32A, Part 1. MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC initial library - showing WISAYNGFTRSTOKFOG (SEQ ID NO. 349)
[0270] Table 32A, Part 2. MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC initial library - showing WISAYNGFTRSTQKFQG (SEO ID NO. 349)
[0271] Table 32B, Part 1. MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC library after 3 rounds of ribosome display selection - showing WISAYNGFTRSTQKFQG (SEQ ID NO. 349)
[0272] Table 32B, Part 2. MABL57 heavy chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC library after 3 rounds of ribosome display selection - showing WISAYNGFTRSTQKFQG (SEO ID NO. 329)
[0273] Table 33A. MABL57 heavy chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57HC initial library
[0274] Table 33B. MABL57 heavy chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) = scFab57HC library after 3 rounds of Ribosome Display selection. Table 34A, Part 1. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57LC initial library showing RASOSVSSFLA (SEQ ID NO. 329)
[0275] Table 34A, Part 2. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57LC initial library showing RASOSVSSFLA (SEO ID NO. 329)
[0276] Table 34B, Part 1. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) -scFab57LC library after 3 rounds of ribosome display selection - showing RASQSVSSFLA (SEQ ID NO. 329)
[0277] Table 34B, Part 2. MABL57 light chain CDR1 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) -scFab57LC library after 3 rounds of ribosome display selection - showing RASQSVSSFLA (SEQ ID NO. 329)
[0278] Table 35A. MABL57 light chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57LC initial library
[0279] Table 35B. MABL57 light chain CDR2 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57LC library after 3 rounds of ribosome display selection
[0280] Table 36A. MABL57 light chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57LC initial library Table 36B. MABL57 light chain CDR3 read frequency (Fi,j=amino acid counts / total counts; i amino acid at j CDR residue) - scFab57LC library after 3 rounds of ribosome display selection
[0281] Table 37A. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 heavy chain CDR1
[0282] Table 37B, Part 1. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 heavy chain CDR2 - showing
[0283] WISAYNGFTRSTQKFQG (SEQ ID NO. 349)
[0284] Table 37B, Part 2. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 heavy chain CDR2 - showing
[0285] WISAYNGFTRSTQKFQG (SEO ID NO. 349)
[0286] Table 37C. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 heavy chain CDR3. Table 38A, Part 1. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 light chain CDR1 - showing - showing
[0287] RASOSVSSFLA (SEQ ID NO. 329)
[0288] Table 38A, Part 2. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 light chain CDR1 - showing RASOSVSSFLA (SEQ ID NO. 329)
[0289] Table 38B. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 light chain CDR2
[0290] Table 38C. Amino acid enrichment factor (EFi,j=frequency of amino acid in 3rdround library / frequency of amino acid in initial library for i amino acid at j CDR residue) for scFab constructs - MABL57 light chain CDR3.
[0291] Table 39A, Part 1. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFab constructs in the heavy chain - showing residues 1-8 of 17
[0292] Table 39A, Part 2. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFab constructs in the heavy chain - showing residues 9-17 of 17
[0293] Table 39B, Part 1. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Kabat numbering) for MABL57 scFab constructs in the light chain - showing residues 1-5 of 11 Table 39B, Part 2. Preferred amino acid substitutions, including wild type CDR amino acids (in bold), at every CDR residue (Rabat numbering) for MABL57 scFab constructs in the light chain - showing residues 6-11 of 11
[0294] Table 40A. Total enrichment factors (sum of all amino acid enrichment factors) for all CDR residues in MABL57 scFab constructs in the heavy chain. CDR region is defined by Kabat numbering.
[0295] Table 40B. Total enrichment factors (sum of all amino acid enrichment factors) for all
[0296] CDR residues in MABL57 scFab constructs in the light chain. CDR region is defined by Kabat numbering.
[0297] Example 19:
[0298] Ten clones were selected and sequenced. Each clone was characterized by a light chain comprising the sequence: EIVLTQSPATLSLSPGERATLSCXAXXSVXXFLXWYQQKPGQAPRLLIFXXSNRAXGI PARFSGSGSGTDFTLTISSLEPEDFAVYYCXQRSNWITFGQGTRLE / 7 / ?77 / 4.4 / <ST7’7 FPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO.327)
[0299] Where the CDRs are indicated in bold; the Kappa sequence is shown in italics.
[0300] Each clone was characterized by a heavy chain comprising the sequence:
[0301] QGQLVQSGAEVKKPGASVKVSCKASGYTFNXYXISWVRQAPGQGLEWMGWISAY NGFTXSTQKFXXRVTLTTDTSTSTAHMELRSLRSDDTAAYYCARXXXDGFDPWGQ GTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSG VHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC / 4 / W7' HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVWDVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFF
[0302] LYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO. 343)
[0303] Again, where the CDRs are indicated in bold; the G1 constant sequence is shown in italics.
[0304] The CDRs for each clone is set forth in Table A, above.
[0305] Example 20. Construction of MABL57 Affinity Maturation Library
[0306] DNA (SEQ ID NO. 282) was synthesized by TWIST Biosciences to include Mabl57 CDR mutations indicated in Table 39A and 39B (parts 1 and 2) and be used for the assembly of a final scFab ribosome display construct / vector (SEQ ID NO. 283), where letters represent bases or equimolar base mix according to the standard IUPAC nucleotide code. SEQ ID NO.283 was generated by a single assembly reaction of four DNA fragments: Fragment 1 (SEQ ID NO. 284), Fragment 2 (SEQ ID NO. 285), Fragment 3 (SEQ ID NO. 286) and Fragment 4 (SEQ ID NO. 287). Assembly reaction was carried out using Overlap Extension PCR (OE-PCR) assembly using 25 uL Q5 polymerase reaction mix (NEB), 142 fmol equimolar of each fragment: 10 cycles at annealing temp of 70o C and 30 second extension at 72o C; followed by addition of 25 pmol forward primer 57PRDnewfwd (SEQ NO. 324), 25 pmol reverse primer 57PRDrev (SEQ NO. 325) and 30 cycles using annealing temperature of 69o C and a 1.5 minute 72o C extension. All PCR reactions using Q5 polymerase were carried out using manufacturer (NEB) recommended programming: 1 cycle 95o C melting for 30 sec.; 30 cycles of 95o C melt for 30 sec, anneal for 15 seconds and extend at 72o C for 30 seconds per kb DNA with a final 2-minute extension at 72o C. Assembly product was gel purified and sequence confirmed by Sanger sequencing. Fragments 1-4 were prepared by PCR. Fragment 1: using 10 ng of SEQ ID NO 282 as template, 30 cycles using 25 pmol forward primer 57PRDnewfwd (SEQ NO. ID 324) and 25 pmol reverse primer TWISTfraglrev (SEQ ID NO. ID 288), and annealing temperature of 69o C and a 30 second extension at 72o C. Fragment 2: using 10 ng of scFab57 (SEQ ID NO. 326) as template, 30 cycles using 25 pmol forward primer TWISTfrag2fwd (SEQ ID NO. 289) and 25 pmol reverse primer TWISTfrag2rev (SEQ NO. ID 290), and annealing temperature of 72o C and a 30 second extension at 72o C. Fragment 3: using 10 ng of SEQ ID NO 282 as template, 30 cycles using 25 pmol forward primer TWISTfrag3fwd (SEQ ID NO. 291) and 25 pmol reverse primer TWISTfrag3rev (SEQ ID NO. ID 292), and annealing temperature of 72o C and a 30 second extension at 72o C. Fragment 4: using 10 ng of scFab57 (SEQ ID NO. 326) as template, 30 cycles using 25 pmol forward primer TWISTfrag4fwd (SEQ ID NO. 293) and 25 pmol reverse primer 57PRDrev (SEQ NO. ID 325), and annealing temperature of 72o C and a 30 second extension at 72o C. All fragments were gel purified and sequence confirmed by Sanger sequencing prior to use in assembly reactions.
[0307] Example 21. Ribosome Display for MABL57 Affinity Maturation
[0308] The scFab MABL57 affinity maturation library was subjected to 7-rounds of ribosome display enrichment. The initial scFab57 affinity maturation library was transcribed into mRNA, which was used for the first round of ribosome display. In vitro translation of the initial library mRNA formed scFab protein / ribosome / mRNA complexes which were selected for binding to biotinylated siglec!2-V2Cl (SEQ ID NO: 261) domain and isolated from unbound scFab / ribosome / mRNA complexes using streptavidin-magnetic beads. After extensive washing of beads, mRNA was eluted using EDTA. Eluted mRNA was recovered and used for first-strand cDNA synthesis and followed by PCR. The scFab RT-PCR product was gel purified and used for OE-PCR assembly to generate full length ribosome display construct. The ribosome display construct DNA could be transcribed to mRNA for a subsequent round of Ribosome Display or the RT-PCR product could be cloned or sequenced for identification of enriched scFab sequences. Affinity matured antibody sequences were identified after 7-rounds of ribosome display: 2 initial rounds at a concentration of 300 nM and 100 nM of biotinylated siglecl2-V2Cl, followed by single rounds of 20 nM, 2 nM, 200 pM and a final 2-rounds at 20 pM of biotinylated siglecl2-V2Cl.
[0309] The following is a detailed description of a single round of ribosome display used for affinity maturation.
[0310] Transcription of scFab57 affinity maturation library DNA was carried out using the HiScribe T7 kit (New England Biolabs). An aliquot of 8 pL DNA (-100 ng - 1000 ng) was mixed with 10 pL 2x buffer and 2 pL of enzyme mix. Transcription was carried out at 37o C for 2 hours. The transcribed mRNA was purified using an RNA clean up column (New England Biolabs) according to the manufacturer’s protocol. The scFab / ribosome / mRNA complexes were formed using PURE Express in vitro translation kit (without release factors; New England Biosystems): 10 pL solution A, 7.5 pL solution B (60 pmol ribosomes), 1 pL disulfide solution 1 (NEB), 1 pL disulfide solution 2 (NEB), 1 pL murine RNase inhibitor (New England Biosystems), 6 pmol of mRNA and water to 25 pL total volume. Translation was carried out at 37o C for 30 minutes and then immediately put on ice. The translation reaction was diluted with 225 pL of WBTH buffer (50 mM Tris pH 7.5, 50 mM magnesium acetate, 120 mM NaCl, 0.5% Tween20, 10% BSA, 100 pg / mL yeast RNA, 2 mg / mL heparin sodium, 0.4 U murine RNase inhibitor). M280 streptavidin coated magnetic beads (Dynal, Invitrogen) were blocked with WBTH buffer for 30-60 min. The diluted translation reaction was pre-cleared with 100 pL M280 beads by incubating for 10-20 min at 4o C, followed by bead removal using a magnet. The pre-cleared translation reaction was incubated with Siglecl2 V2Cl-biotin (300 nM-20 pM) for 1 hr rotating at 4o C (for lower concentrations 200-20 pM biotinylated siglecl2 V2C1, incubation was extended to 2-3 hrs). scFab / ribosome / mRNA complexes bound to Siglecl2 V2Cl-biotin were selected by incubating with 50 pL M280 precleared beads for 15-30 minutes, rotating at 4° C. The magnetic beads were isolated using a magnet and washed with 1 mL of ice-cold wash buffer (50 mM Tris pH 7.5, 50 mM magnesium acetate, 150 mM NaCl, 0.1% Tween20). Magnetic beads were isolated using a magnet. The wash step was repeated for a total of 5 washes. The magnetic bead-bound scFab / ribosome / mRNA complexes were eluted by incubating with 50 pL of elution solution (50 mM EDTA in 50 mM Tris pH 7.5, 150 mM NaCl, 0.5% Tween20, 10 pg / mL yeast RNA, 0.4 U RNase inhibitor) for 30 minutes rotating at room temperature. The elution was recovered from magnetic beads using a magnet. The eluted mRNA (plus yeast carrier RNA) was purified using a 10 ug Monarch RNA Clean up Kit (New England Biolabs). In preparation for first-strand cDNA synthesis, 6 pL of the 8 uL water elution from the Monarch 10 ug column was pre-annealed with 2 pL of 10 pM scFabPRD59ntrev primer (SEQ ID NO: 298) by incubating at 65oC for 5 min and immediately put on ice. Using the Protocript II first-strand cDNA kit (NEB) and the 8 pL pre-annealed RNA solution, a 20 pL first-strand reaction was carried out at 42o C for 1 hr, followed by a 5-minute 80o C heat kill. Full length ribosome display scFab library DNA was prepared by OE-PCR assembly of a 5’ fragment (containing light and heavy chain variable region sequence from the scFab library) with a 3’ fragment of constant sequence (SEQ ID NO. 299). The 5’ fragment was prepared by PCR: 30 cycles using 25 uL 2x Q5 polymerase (NEB), a 5 uL aliquot of cDNA (from eluted mRNA), 25 pmol of forward primer scFabPRDT71ongfwd (SEQ ID NO. 300) and 25 pmol of reverse primer CDR3fraglnewrev (SEQ ID NO. 301), an annealing temperature of 72o C and a 1 -minute extension at 72o C. The 3’ fragment was prepared by PCR: 30 cycles using 25 uL 2x Q5 polymerase (NEB), 10 ng of scFab57 template (SEQ ID NO. 326), 25 pmol of forward primer CDR3frag2fwd2 (SEQ ID NO. 323) and 25 pmol of reverse primer scFabPRD59ntrev (SEQ ID NO. 298), an annealing temperature of 69o C and a 30 second extension at 72o C. Both 5’ and 3’ fragments were gel purified on 1% agarose and assembled into the full-length ribosome display scFab library by OE-PCR assembly: initial 10 cycles using 25 uL 2x Q5 polymerase (NEB), equimolar (3-20 finol) of the 5’ and 3’ fragment with annealing temp of 72o C and 1-minute 72o C extension; these 10 cycles were followed by addition of 25 pmol of forward primer scFabPRDT71ongfwd (SEQ ID NO. 300) and reverse primer scFabPRD59ntrev (SEQ ID NO. 298), and an additional 30 cycles with annealing temperature of 72o C and a 1.5-minute extension at 72o. The OE-PCR product (full-length scFab ribosome display library) was gel purified and could be used for a subsequent round of ribosome display or cloning and sequencing.
[0311] After the last round of ribosome display, for cloning / sequencing purposes, the enriched library was subcloned into the kanamycin resistant pUCGW vector (Azenta / Genewiz). Fragments from the scFab library containing heavy and light chain variable sequence were amplified by 30 cycles of PCR using 25 uL 2x Q5 polymerase (NEB), with annealing temperature 72o C, 1-minute 72o C extension using 25 pmol forward primer pUCinsertfwd (SEQ ID NO. 294) and 25 pmol reverse primer pUCinsertrev (SEQ ID NO. 295). The pUCGW vector was prepared for assembly cloning using PCR: 30 cycles using 25 uL 2x Q5 polymerase (NEB) with annealing temperature of 71 o C, 1.5 -minute 72o C extension, 25 pmol forward primer pUCkanGWfwd (SEQ ID NO. 296), 25 pmol reverse primer pUCkanGWrev (SEQ ID NO. 297) using 10 ng of pUCGW-kan vector as template. Both scFab and prepared pUCGW PCR fragments were gel purified on 1% agarose and assembled using NEBuilder HiFi DNA Assembly kit (New England Biolabs catalog) according to manufacturer’s protocol. Single colony clones were isolated from kanamycin containing agar plates and heavy and light chain variable regions Sanger sequenced using primers seqHCfwd (SEQ ID NO. 321) and seqLCfwd (SEQ ID NO. 322). Nine unique MABL57 daughter clones were identified: 57.3, 57.4, 57.8, 57.10, 57.12, 57.13, 57.16, 57.17 and 57.19.
[0312] Example 21. Conversion of scFab Clones to Full-Length Human IgGl Antibodies
[0313] For preparation of full-length human IgGl antibodies, 5 unique heavy chain sequences were assembled into a heavy chain fragment of the zeocin-resistant biscistronic pTrioz mammalian expression vector (Invivogen) containing MABL57 IgGl heavy chain and MABL57 kappa light chain sequence; these 5 MABL57 daughter heavy chain sequences were used to generate pTrioz light chain fragments for the assembly of 7 unique light chain fragments to generate 8 unique IgGl / kappa MABL57 daughter clones in the pTrioz vector. The MABL57 IgGl heavy chain pTrioz fragment (SEQ ID NO. 302) was generated by PCR using 25 uL 2x Q5 polymerase (NEB) ,10 ng of MABL57 pTrioz (SEQ ID NO. 303) as template, 25 pmol of forward primer pTriozHCfwd (SEQ ID NO. 304) and 25 pmol of reverse primer pTriozHCrev (SEQ ID NO. 305), annealing temperature of 72o C and a 4.5- minute 72o C extension. The 5 heavy chain MABL57 daughter sequences in pTrioz were prepared by 5 separate assembly cloning reactions using NEBuilder HiFi DNA Assembly reaction mix (NEB, according to manufacturer’s protocol) with the heavy chain pTrioz fragment and 5 synthesized DNA blocks (IDT) containing the unique heavy V-region sequences (SEQ ID NO. 306, SEQ ID NO. 307, SEQ ID NO. 308, SEQ ID NO. 309 and SEQ ID NO. 310). Single clone colonies for each reaction were grown on zeocin containing agar plates and the 5 heavy chain sequences in pTrioz were verified by Sanger sequencing. For each of the 5 heavy chain pTrioz construct, a pTrioz light chain fragment (SEQ ID NO. 311; this sequence contains parent 57 heavy chain sequence but shows common sequence to accept light chain DNA block sequence) was prepared by PCR using 10 ng of the heavy chain pTrioz construct as template, 25 pmol of forward primer pTriozLC2fwd (SEQ ID NO. 312) and 25 pmol of reverse primer pTriozLC2rev (SEQ ID NO. 313), annealing temperature of 72o C and a 4.5-minute 72o C extension. Eight unique MABL57 IgGl / kappa daughter sequences were generated by 8 separate assembly cloning reactions using NEBuilder HiFi DNA Assembly reaction mix (NEB, according to manufacturer’s protocol) with the appropriate heavy chain pTrioz light chain fragment and one of seven synthesized DNA blocks (IDT) containing the unique kappa chain V-region sequence (SEQ ID NO. 314, SEQ ID NO. 315, SEQ ID NO. 316, SEQ ID NO. 317, SEQ ID NO. 318, SEQ ID NO. 319 and SEQ ID NO. 320). Single clone colonies for each reaction were grown on zeocin containing agar plates and the 8 heavy chain V-region sequences in pTrioz were verified by Sanger sequencing.
[0314] Example 22. Transient Expression and Purification of Affinity Matured Human MABL57 IgGl Antibodies
[0315] Eight separate Expi293 cell transfections were carried out with each of the MABL57 affinity matured daughter clone’s DNA using the ExpiFectamine Transfection Kit (ThermoFisher) and according to the manufacturer’s protocol. After 6-days of transient production, media was harvested by centrifugation (10 minutes at 5,000 g) and clarified by 0.45 micron filtration. Clarified media was passed over a Protein-A sepharose column (Pierce) overnight at 4o C. The Protein-A Sepharose column was washed with 20-column volumes of PBS and eluted with 5 column volumes of elution buffer (0.1M acetic acid / O.lM NaCl, pH 3.5) and neutralized with 0.25 mL neutralization buffer (IM Tris, pH 8.0). For each antibody, protein-containing eluted fractions were combined and concentrated using an Amicon Ultra4 (10 kD MWCO) centrifugal filtering unit (Millipore). Concentrated antibody was buffer exchanged into PBS using a PD-10 column (Cytiva). Antibody concentrations were determined by absorbance at 280 nm using an extinction coefficient of 1.3 A280 units per 1 mg / mL antibody concentration.
[0316] Example 23. Saturation Binding of Affinity Matured MABL57 Human IgGl Antibodies Saturation binding curves were generated by ELISA. Siglecl2-V2Cl (100 uL of lug / mL) was absorbed to a 96-well polystyrene plate (NUNC) overnight at 4o C. Wells were blocked with 250 uL 3% BSA for 1 hour at room temperature. 100 uL per well of antibody was incubated for 3 hours at room temperature. Antibody concentration was titrated from 1 uM to 5.6 pM. After primary incubation, wells were washed 5 times with 300 uL TBS / Tween20 (0.5%). Wells were incubated with goat-anti human kappa chain HRP conjugate (Bethyl; 1 / 10,000 in TBS / Tween20 + 0.3 mg / mL BSA) for 30 minutes, room temperature. Wells were washed 6 times with 300 uL TBS / Tween20 (0.5%). The wells were developed by addition of 100 uL TMB / hydrogen peroxide HRP substrate (ThermoFisher) and reaction stopped after 5 minutes with 50 uL 2M sulfuric acid. Substrate turnover was quantified by measuring the optical density at 450 nm on a BioTek CYTATION™ 5 instrument (Winooski, VT). Optical densities were background subtracted and normalized with the 1 uM antibody concentration optical density for calculated percent-saturation binding.
[0317] The invention includes nucleic acids comprising one or more of the sequences set forth in the table below and their expression products:
[0318]
[0319]
Claims
CLAIMS An antibody, wherein the antibody binds a sialic acid binding-immunoglobulin type lectin (siglec) and wherein the antibody comprises at least one human antibody variable domain, wherein the variable heavy chain sequence of SEQ ID NO: 4 comprises: a CDR1 sequence of SEQ ID NO: 32 comprising one or more substitutions as indicated in Table 29A, a CDR2 sequence of SEQ ID NO: 38 comprising one or more substitutions as indicated in Table 29A, and a CDR3 sequence of SED ID NO: 44 comprising one or more substitutions as indicated in Table 29 A; and wherein the variable light chain sequence of SEQ ID NO: 11 comprises: a CDR1 sequence of SEQ ID NO: 51 comprising one or more substitutions as indicated in Table 29B, a CDR2 sequence of SEQ ID NO: 57 comprising one or more substitutions as indicated in Table 29B, and a CDR3 sequence of SEQ ID NO: 63 comprising one or more substitutions as indicated in Table 29B. The antibody of claim 1, wherein the variable heavy chain sequence of SEQ ID NO: 4 comprises: a CDR1 sequence of SEQ ID NO: 32 comprising one or more substitutions as indicated in Table 39A, a CDR2 sequence of SEQ ID NO: 38 comprising one or more substitutions as indicated in Table 39A, and a CDR3 sequence of SED ID NO: 44 comprising one or more substitutions as indicated in Table 39A; and wherein the variable light chain sequence of SEQ ID NO: 11 comprises: a CDR1 sequence of SEQ ID NO: 51 comprising one or more substitutions as indicated in Table 39B, a CDR2 sequence of SEQ ID NO: 57 comprising one or more substitutions as indicated in Table 39B, and a CDR3 sequence of SEQ ID NO: 63 comprising one or more substitutions as indicated in Table 39B. The antibody of claim 1, wherein the antibody binds a sialic acid binding- immunoglobulin type lectin (siglec) and wherein the antibody comprises at least one human antibody variable domain. An antibody, wherein the antibody binds a sialic acid binding-immunoglobulin type lectin (siglec) and wherein the antibody comprises at least one human antibody variable domain, wherein the variable light chain CDR1 is selected from:(i) RASQSVSSFLA (SEQ ID NO. 329);(ii) KASHSVSSFLS (SEQ ID NO. 330);(iii) RASQSVSSFLS (SEQ ID NO. 331);(iv) RASHSVSSFLS (SEQ ID NO. 332);(v) KASQSVSSFLS (SEQ ID NO. 333); or(vi) TASQSVSSFLS (SEQ ID NO. 334); the variable light chain CDR2 is selected from:(i) DASNRAT (SEQ ID NO. 336);(ii) DASNRAN (SEQ ID NO. 337);(iii) YTSNRAT (SEQ ID NO. 338); or(iv) DTSNRAT (SEQ ID NO. 339);CDR3 is selected from:(i) QQRSNWIT (SEQ ID NO. 341); or(ii) HQRSNWIT (SEQ ID NO. 342). An antibody, wherein the antibody binds a sialic acid binding-immunoglobulin type lectin (siglec) and wherein the antibody comprises at least one human antibody variable domain, wherein the variable heavy chain CDR1 is selected from:(i) NNYGIS (SEQ ID NO. 345);(ii) NSYGIS (SEQ ID NO. 346); or(ii) NKYGIS (SEQ ID NO. 347); the variable heavy chain CDR2 is selected from:(i) WISAYNGFTRSTQKFQG (SEQ ID NO. 349); or(ii) WISAYNGFTRSTQKFNG (SEQ ID NO. 350); the variable heavy chain CDR3 is:(i) DGGDGFDP (SEQ ID NO. 352).
6. An antibody comprises a variable light chain comprises the sequence:EIVLTQSPATLSLSPGERATLSCXAXXSVXXFLXWYQQKPGQAPRLLIFXXSN RAXGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCXQRSNWITFGQGTRLE7A ? ARTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC EQ ID NO. 327); wherein each CDR is indicated in bold; a Kappa sequence is shown in italics; and CDR1 is selected from:(i) RASQSVSSFLA (SEQ ID NO. 329);(ii) KASHSVSSFLS (SEQ ID NO. 330);(iii) RASQSVSSFLS (SEQ ID NO. 331);(iv) RASHSVSSFLS (SEQ ID NO. 332);(v) KASQSVSSFLS (SEQ ID NO. 333); or(vi) TASQSVSSFLS (SEQ ID NO. 334);CDR2 is selected from:(i) DASNRAT (SEQ ID NO. 336);(ii) DASNRAN (SEQ ID NO. 337);(iii) YTSNRAT (SEQ ID NO. 338); or(iv) DTSNRAT (SEQ ID NO. 339);CDR3is selected from:(i) QQRSNWIT (SEQ ID NO. 341); or(ii) HQRSNWIT (SEQ ID NO. 342).
7. An antibody comprising a variable heavy chain comprises the sequence:QGQLVQSGAEVKKPGASVKVSCKASGYTFNXYXISWVRQAPGQGLEWMG WISAYNGFTXSTQKFXXRVTLTTDTSTSTAHMELRSLRSDDTAAYYCARXX XDGFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKY YYYiN ¥^NEYYiS>CADKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV TCVWD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR WSVL TVLHQD W LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLV KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO. 343); wherein each CDR is indicated in bold; a G1 constant sequence is shown in italics;CDR1 is selected from:(i) NNYGIS (SEQ ID NO. 345);(ii) NSYGIS (SEQ ID NO. 346); or(ii) NKYGIS (SEQ ID NO. 347);CDR2 is selected from:(i) WISAYNGFTRSTQKFQG (SEQ ID NO. 349); or(ii) WISAYNGFTRSTQKFNG (SEQ ID NO. 350);CDR3, XXXDGFDP (SEQ ID NO. 351); is:(i) DGGDGFDP (SEQ ID NO. 352).
8. The antibody of claim 6 or 7, wherein each CDRs is independently selected from Table A.
9. The antibody of claim 8, wherein each CDR is selected from the CDRs of a clone of Table A.
10. The antibody of any one of claims 1-9, wherein the antibody does not bind to siglec 7 or siglec 9.
11. The antibody of any one of claims 1-10, wherein the siglec is associated with a cell.
12. The antibody of claim 11, wherein the cell is a cancer cell.
13. A method of treating a therapeutic indication in a subject, the method comprising the use of the antibody of any one of claims 1-12.
14. The method of claim 13, wherein the therapeutic indication comprises a cancer- related indication.
15. The method of claim 14, wherein the cancer-related indication comprises leukemia.
16. The method of claim 15, wherein the leukemia comprises AML and / or CML.
17. The method of claim 13, wherein the antibody is administered to the subject by injection or infusion.
18. A method of detecting siglecl2 in a subject or a subject sample, the method comprising contacting the subject or subject sample with the antibody of any one of claims 1-12.
19. The method of claim 18, wherein the antibody comprises a detectable label.122
